Search

Your search keyword '"von Wyl V"' showing total 229 results
Start Over Author "von Wyl V"
229 results on '"von Wyl V"'

1. Long-term trajectories of densely reported depressive symptoms during an extended period of the COVID-19 pandemic in Switzerland: Social worries matter

Author

Probst-Hensch, N., Imboden, M., Jeong, A., Keidel, D., Vermes, T., Witzig, M., Cullati, S., Tancredi, S., Noor, N., Rodondi, P.-Y., Harju, E., Michel, G., Frank, I., Kahlert, C., Cusini, A., Rodondi, N., Chocano-Bedoya, P.O., Bardoczi, J.B., Stuber, M.J., Vollrath, F., Fehr, J., Frei, A., Kaufmann, M., Geigges, M., von Wyl, V., Puhan, M.A., Albanese, E., Crivelli, L., and Lovison, G.F.

Published
2024
Full Text
View/download PDF

2. Changes in socioeconomic resources and mental health after the second COVID-19 wave (2020-2021): a longitudinal study in Switzerland

Author

Tancredi, S., Ulyte, A., Wagner, C., Keidel, D., Witzig, M., Imboden, M., Probst-Hensch, N., Amati, R., Albanese, E., Levati, S., Crivelli, L., Kohler, P., Cusini, A., Kahlert, C., Harju, E., Michel, G., Ludi, C., Ortega, N., Baggio, S., Chocano-Bedoya, P., Rodondi, N., Ballouz, T., Frei, A., Kaufmann, M., Von Wyl, V., Lorthe, E., Baysson, H., Stringhini, S., Schneider, V., Kaufmann, L., Wieber, F., Volken, T., Zysset, A., Dratva, J., Cullati, S., and Corona Immunitas Research Group

Abstract

BACKGROUND: During the 2020/2021 winter, the labour market was under the impact of the COVID-19 pandemic. Changes in socioeconomic resources during this period could have influenced individual mental health. This association may have been mitigated or exacerbated by subjective risk perceptions, such as perceived risk of getting infected with SARS-CoV-2 or perception of the national economic situation. Therefore, we aimed to determine if changes in financial resources and employment situation during and after the second COVID-19 wave were prospectively associated with depression, anxiety and stress, and whether perceptions of the national economic situation and of the risk of getting infected modified this association. METHODS: One thousand seven hundred fifty nine participants from a nation-wide population-based eCohort in Switzerland were followed between November 2020 and September 2021. Financial resources and employment status were assessed twice (Nov2020-Mar2021, May-Jul 2021). Mental health was assessed after the second measurement of financial resources and employment status, using the Depression, Anxiety and Stress Scale (DASS-21). We modelled DASS-21 scores with linear regression, adjusting for demographics, health status, social relationships and changes in workload, and tested interactions with subjective risk perceptions. RESULTS: We observed scores above thresholds for normal levels for 16% (95%CI = 15-18) of participants for depression, 8% (95%CI = 7-10) for anxiety, and 10% (95%CI = 9-12) for stress. Compared to continuously comfortable or sufficient financial resources, continuously precarious or insufficient resources were associated with worse scores for all outcomes. Increased financial resources were associated with higher anxiety. In the working-age group, shifting from full to part-time employment was associated with higher stress and anxiety. Perceiving the Swiss economic situation as worrisome was associated with higher anxiety in participants who lost financial resources or had continuously precarious or insufficient resources. CONCLUSION: This study confirms the association of economic stressors and mental health during the COVID-19 pandemic and highlights the exacerbating role of subjective risk perception on this association.

Published
2023

7. Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.

Author

Kamm, Christian Philipp, Barin, L., Gobbi, C., Pot, C., Calabrese, P., Salmen, A., Achtnichts, L., Kesselring, J., Puhan, M. A., von Wyl, V., For the Swiss Multiple Sclerosis Registry (SMSR), Anderseck, Bernd, Calabrese, Pasquale, Chan, Andrew, Disanto, Giulio, Engelhardt, Britta, Gobbi, Claudio, Haussler, Roger, Kamm, Christian P., and Kagi, Susanne

Subjects
PATIENT satisfaction, MULTIPLE sclerosis, PATIENT decision making, DECISION making, LOGISTIC regression analysis
Abstract

Background: Patient satisfaction is predictive of adherence, malpractice litigation and doctor-switching. Objective: To investigate which factors of the first diagnostic consultation (FDC) influence patient satisfaction and which topics persons with multiple sclerosis (PwMS) thought were missing. Methods: Using retrospective patient-reported data of the Swiss Multiple Sclerosis Registry from PwMS with relapsing disease onset, we fitted ordered logistic regression models on satisfaction with FDC, with socio-demographic and FDC features as explanatory factors. Results: 386 PwMS diagnosed after 1995 were included. Good satisfaction with the FDC was associated with a conversation more than 20 min [multivariable odds ratio, 95% confidence interval 3.9 (2.42; 6.27)], covering many topics [1.35 (1.19; 1.54) per additional topic], the presence of a significant others [1.74 (1.03; 2.94) ], and shared decision making [3.39 (1.74; 6.59)]. Not receiving a specific diagnosis was main driver for low satisfaction [0.29 (0.15; 0.55)]. Main missing topics concerned long-term consequences (reported by 6.7%), psychological aspects (6.2%) and how to obtain support and further information (5.2%). Conclusions: A conversation of more than 20 min covering many MS relevant topics, a clear communication of the diagnosis, the presence of a close relative or significant other, as well as shared decision making enhanced patient satisfaction with the FDC. ClinicalTrials.gov Identifier: NCT02980640 [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

8. Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection

Author

Metzner, K. J., Scherrer, A. U., Preiswerk, B., Joos, B., von Wyl, V., Leemann, C., Rieder, P., Braun, D., Grube, C., Kuster, H., Boni, J., Yerly, S., Klimkait, T., Aubert, V., Furrer, H., Battegay, M., Vernazza, P. L., Cavassini, M., Calmy, A., Bernasconi, E., Weber, R., Gunthard, H. F., Barth, J., Bucher, H. C., Burton-Jeangros, C., Egger, M., Elzi, L., Fehr, J., Fellay, J., Fux, C. A., Gorgievski, M., Gunthard, H., Haerry, D., Hasse, B., Hirsch, H. H., Hosli, I., Kahlert, C., Kaiser, L., Keiser, O., Kovari, H., Kouyos, R., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Metzner, K., Muller, N., Nadal, D., Pantaleo, G., Rauch, A., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schoni-Affolter, F., Schupbach, J., Speck, R., Taffe, P., Tarr, P., Telenti, A., Trkola, A., University of Zurich, Metzner, Karin J, Swiss HIV Cohort Study, Aubert, V., Barth, J., Battegay, M., Bernasconi, E., Böni, J., Bucher, HC., Burton-Jeangros, C., Calmy, A., Cavassini, M., Egger, M., Elzi, L., Fehr, J., Fellay, J., Furrer, H., Fux, CA., Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kovari, H., Kouyos, R., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Metzner, K., Müller, N., Nadal, D., Pantaleo, G., Rauch, A., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schöni-Affolter, F., Schüpbach, J., Speck, R., Taffé, P., Tarr, P., Telenti, A., and Trkola, A.

Subjects
Male, HIV Infections, Drug resistance, Polymerase Chain Reaction, law.invention, 10234 Clinic for Infectious Diseases, Cohort Studies, 0302 clinical medicine, law, Adolescent, Adult, Aged, Alleles, Cluster Analysis, Drug Resistance, Viral, Female, Genetic Variation, HIV Infections/transmission, HIV Infections/virology, HIV-1/drug effects, HIV-1/genetics, Humans, Middle Aged, Phylogeny, Sequence Analysis, DNA, Switzerland, Young Adult, Immunology and Allergy, 030212 general & internal medicine, Young adult, 610 Medicine & health, Polymerase chain reaction, ddc:616, 0303 health sciences, biology, Transmission (medicine), Resistance mutation, 3. Good health, Integrase, Infectious Diseases, 2723 Immunology and Allergy, Peripheral blood mononuclear cell, 03 medical and health sciences, Allele, 030304 developmental biology, HIV-1/drug effects/genetics/isolation & purification, 2725 Infectious Diseases, HIV Infections/transmission/virology, Virology, Immunology, HIV-1, biology.protein
Abstract

Background. Drug-resistant human immunodeficiency virus type 1 (HIV-1) minority variants (MVs) are present in some antiretroviral therapy (ART)–naive patients. They may result from de novo mutagenesis or transmission. To date, the latter has not been proven. Methods. MVs were quantified by allele-specific polymerase chain reaction in 204 acute or recent seroconverters from the Zurich Primary HIV Infection study and 382 ART-naive, chronically infected patients. Phylogenetic analyses identified transmission clusters. Results. Three lines of evidence were observed in support of transmission of MVs. First, potential transmitters were identified for 12 of 16 acute or recent seroconverters harboring M184V MVs. These variants were also detected in plasma and/or peripheral blood mononuclear cells at the estimated time of transmission in 3 of 4 potential transmitters who experienced virological failure accompanied by the selection of the M184V mutation before transmission. Second, prevalence between MVs harboring the frequent mutation M184V and the particularly uncommon integrase mutation N155H differed highly significantly in acute or recent seroconverters (8.2% vs 0.5%; P < .001). Third, the prevalence of less-fit M184V MVs is significantly higher in acutely or recently than in chronically HIV-1–infected patients (8.2% vs 2.5%; P = .004). Conclusions. Drug-resistant HIV-1 MVs can be transmitted. To what extent the origin—transmission vs sporadic appearance—of these variants determines their impact on ART needs to be further explored.

Published
2013

9. Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes

Author

Audelin, A., Castagna, A., Costagliola, D., Cozzi-Lepri, A., De Luca, A., De Wit, S., de Wolf, F., Dorrucci, M., Duval, X., Fatkenheuer, G., Garcia, F., Ghosn, J., Gunthard, H., Jansen, K., Judd, A., Ledergerber, B., Lo Caputo, S., Lodwick, R., Masquelier, B., Meyer, L., Mocroft, A., Mussini, C., Noguera-Julian, A., Obel, N., Paraskevis, D., Paredes, R., Perez-Hoyos, S., Phillips, A., Pillay, D., Podzamczer, D., Ramos, J. T., Stephan, C., Tookey, P. A., Torti, C., Touloumi, G., van Sighem, A., Warsawski, J., Zangerle, R., Warszawski, J., Dabis, F., Krause, M. M., Leport, C., Reiss, P., Prins, M., Bucher, H., Sabin, C., Gibb, D., Del Amo, J., Thorne, C., Kirk, O., Antinori, A., d'Arminio Monforte, A., Brockmeyer, N., Ramos, J., Battegay, M., Rauch, A., Tookey, P., Casabona, J., Miro, J. M., de Wit, S., Goetghebuer, T., Teira, R., Garrido, M., Haerry, D., Weller, I., d'Arminio-Monforte, A., Grarup, J., Chene, G., Bohlius, J., Bouteloup, V., Egger, M., Engsig, F., Furrer, H., Lambotte, O., Lewden, C., Matheron, S., Miro, J., Puoti, M., Reekie, J., Scherrer, A., Smit, C., Sterne, J., Thiebaut, R., von Wyl, V., Wittkop, L., Ledergerber, Bruno, Cohere, Cohort, Castagna, Antonella, Other departments, Amsterdam institute for Infection and Immunity, Amsterdam Public Health, Global Health, and Infectious diseases

Subjects
Adult, Male, medicine.medical_specialty, Efavirenz, Infectious Disease, HIV Infections, Settore MED/17 - MALATTIE INFETTIVE, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, antiretroviral agent, Internal medicine, Medicine, Immunology and Allergy, Humans, Protease inhibitor (pharmacology), HIV Infection, 030212 general & internal medicine, Anti-Retroviral Agents, CD4 Lymphocyte Count, Female, Middle Aged, Treatment Failure, Viral Load, Generalized estimating equation, HIV cohort study, business.industry, CD4 lymphocyte count, Raltegravir, Confidence interval, 3. Good health, VIROLOGIC FAILURE, Infectious Diseases, chemistry, 030220 oncology & carcinogenesis, Immunology, Cohort, triple-class virologic failure, HIV-1, Anti-Retroviral Agent, business, Viral load, medicine.drug, Human
Abstract

Background. Low CD4+ T-cell counts are the main factor leading to clinical progression in human immunodeficiency virus type 1 (HIV-1) infection. We aimed to investigate factors affecting CD4+ T-cell counts after triple-class virological failure.Methods. We included individuals from the COHERE database who started antiretroviral therapy from 1998 onward and who experienced triple-class virological failure. CD4+ T-cell counts obtained after triple-class virologic failure were analyzed using generalized estimating equations.Results. The analyses included 2424 individuals with a total of 23 922 CD4+ T-cell count measurements. In adjusted models (excluding current viral load and year), CD4+ T-cell counts were higher with regimens that included boosted protease inhibitors (increase, 22 cells/μL [95% confidence interval CI, 3.9-41]; P =. 017) or drugs from the new classes (increase, 39 cells/μL [95% CI, 15-62]; P =. 001), compared with nonnucleoside reverse-transcriptase inhibitor-based regimens. These associations disappeared when current viral load and/or calendar year were included. Compared with viral levels of 5.5 log10 copies/mL were associated with CD4+ T-cell count decreases of 51, 84, 137, and 186 cells/μL, respectively (P

Published
2013

10. The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients

Author

Beerenwinkel N Montazeri H Schuhmacher H Knupfer P von Wyl V Furrer H Battegay M Hirschel B

Abstract

The success of combination antiretroviral therapy is limited by the evolutionary escape dynamics of HIV 1. We used Isotonic Conjunctive Bayesian Networks (I CBNs) a class of probabilistic graphical models to describe this process. We employed partial order constraints among viral resistance mutations which give rise to a limited set of mutational pathways and we modeled phenotypic drug resistance as monotonically increasing along any escape pathway. Using this model the individualized genetic barrier (IGB) to each drug is derived as the probability of the virus not acquiring additional mutations that confer resistance. Drug specific IGBs were combined to obtain the IGB to an entire regimen which quantifies the virus' genetic potential for developing drug resistance under combination therapy. The IGB was tested as a predictor of therapeutic outcome using between 2185 and 2631 treatment change episodes of subtype B infected patients from the Swiss HIV Cohort Study Database a large observational cohort. Using logistic regression significant univariate predictors included most of the 18 drugs and single drug IGBs the IGB to the entire regimen the expert rules based genotypic susceptibility score (GSS) several individual mutations and the peak viral load before treatment change. In the multivariate analysis the only genotype derived variables that remained significantly associated with virological success were GSS and with 10 fold stronger association IGB to regimen. When predicting suppression of viral load below 400 cps/ml IGB outperformed GSS and also improved GSS containing predictors significantly but the difference was not significant for suppression below 50 cps/ml. Thus the IGB to regimen is a novel data derived predictor of treatment outcome that has potential to improve the interpretation of genotypic drug resistance tests.

Published
2013

11. Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load

Author

Alizon S, von Wyl V, Stadler T, Kouyos RD, Yerly S, Hirschel B, Boni J, Shah C, Klimkait T, Furrer H, Rauch A, Vernazza PL, and Bernasconi E

Abstract

HIV virulence i.e. the time of progression to AIDS varies greatly among patients. As for other rapidly evolving pathogens of humans it is difficult to know if this variance is controlled by the genotype of the host or that of the virus because the transmission chain is usually unknown. We apply the phylogenetic comparative approach (PCA) to estimate the heritability of a trait from one infection to the next which indicates the control of the virus genotype over this trait. The idea is to use viral RNA sequences obtained from patients infected by HIV 1 subtype B to build a phylogeny which approximately reflects the transmission chain. Heritability is measured statistically as the propensity for patients close in the phylogeny to exhibit similar infection trait values. The approach reveals that up to half of the variance in set point viral load a trait associated with virulence can be heritable. Our estimate is significant and robust to noise in the phylogeny. We also check for the consistency of our approach by showing that a trait related to drug resistance is almost entirely heritable. Finally we show the importance of taking into account the transmission chain when estimating correlations between infection traits. The fact that HIV virulence is at least partially heritable from one infection to the next has clinical and epidemiological implications. The difference between earlier studies and ours comes from the quality of our dataset and from the power of the PCA which can be applied to large datasets and accounts for within host evolution. The PCA opens new perspectives for approaches linking clinical data and evolutionary biology because it can be extended to study other traits or other infectious diseases.

Published
2010

12. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

Author

Worm, S, Bower, M, Reiss, P, Bonnet, F, Law, M, Fätkenheuer, G, d'Arminio Monforte, A, Abrams, D, Grulich, A, Fontas, E, Kirk, O, Furrer, H, Wit, S, Phillips, A, Lundgren, J, Sabin, C, Butcher, D, Delforge, M, Fanti, I, Franquet, X, Geffard, S, Gras, L, Helweg Larsen, J, Hillebregt, M, Kamara, D, Kjær, J, Krum, E, McManus, H, Meidahl, P, Mocroft, A, Nielsen, J, Powderl, W, Rickenbach, M, Rode, R, Ryom, L, Salbøl Brandt, R, Schmidt Iversen, J, Shortman, N, Sjøl, A, Smith, C, Torres, F, Tverland, J, Wright, S, Zaheri, S, de Wolf, F, Smidt, J, Ristola, M, Katlama, C, Viard, J, Girard, P, Livrozet, J, Vanhems, P, Pradier, C, Dabis, F, Neau, D, Rockstroh, J, Schmidt, R, Degen, O, van Lunzen, J, Stellbrink, H, Staszewski, S, Bogner, J, Gargalianos, P, Kosmidis, J, Perdios, J, Xylomenos, G, Filandras, A, Karabatsaki, E, Panos, G, Sambatakou, H, Banhegyi, D, Mulcahy, F, Burke, M, Turner, D, Yust, I, Hassoun, G, Pollack, S, Maayan, S, Vella, S, Esposito, R, Mazeu, I, Mussini, C, Arici, C, Pristera, R, Gabbuti, A, Mazzotta, F, Lichtner, M, Vullo, V, Boer, K, Geerlings, S, Godfried, M, Kuijpers, T, Lange, J, Nellen, F, Pajkrt, D, Prins, J, Scherpbier, H, Vrouenraets, S, Wit, F, van Vugt, M, van der Meer, J, van der Poll, T, van der Valk, M, Chirianni, A, Gargiulo, M, Montesarchio, E, Antonucci, G, Narciso, P, Testa, A, Vlassi, C, Zaccarelli, M, Castagna, A, Gianotti, N, Lazzarin, A, Galli, M, Ridolfo, A, Rozentale, B, Zeltina, I, Chaplinskas, S, Hemmer, R, Staub, T, Bruun, J, Maeland, A, Ormaasen, V, Lowe, S, Oude Lashof, A, Schreij, G, Gasiorowski, J, Knysz, B, Bakowska, E, Horban, A, Flisiak, R, Grzeszczuk, A, Boron Kaczmarska, A, Parczewski, M, Pynka, M, Beniowski, M, Mularska, E, Trocha, H, Jablonowska, E, Malolepsza, E, Wojcik, K, Antunes, F, Caldeira, L, Doroana, M, Mansinho, K, Maltez, F, Bravenboer, B, Pronk, M, Duiculescu, D, Rakhmanova, A, Zakharova, N, Buzunova, S, Jevtovic, D, Mokráš, M, Staneková, D, Tomazic, J, González Lahoz, J, Labarga, P, Medrano, J, Soriano, V, Moreno, S, Rodriguez, J, Bravo, I, Clotet, B, Jou, A, Paredes, R, Puig, J, Tural, C, Gelinck, L, Nouwen, J, Rijnders, B, Schurink, C, Slobbe, L, Verbon, A, de Vries Sluijs, T, van der Ende, M, van der Feltz, M, Gatell, J, Miró, J, Domingo, P, Gutierrez, M, Mateo, G, Sambeat, M, Karlsson, A, Flamholc, L, Ledergerber, B, Weber, R, Cavassini, M, Francioli, P, Boffi, E, Hirschel, B, Battegay, M, Elzi, L, Chentsova, N, Kravchenko, E, Driessen, G, Hartwig, N, Frolov, V, Kutsyna, G, Servitskiy, S, Krasnov, M, Barton, S, Johnson, A, Mercey, D, Johnson, M, Murphy, M, Scullard, G, Weber, J, Fisher, M, Leen, C, Branger, J, Åkerlund, B, Morfeldt, L, S.u.n.d.s.t.r.ö.m. , A, Thulin, G, Koppel, K, Ho̊kangård, C, Angarano, G, Antinori, A, Armignacco, O, Castelli, F, Cauda, R, Di Perri, G, Iardino, R, Ippolito, G, Moroni, M, Perno, C, Viale, P, Von Schlosser, F, Ammassari, A, Andreoni, M, Balotta, C, Bonfanti, P, Bonora, S, Borderi, M, Capobianchi, M, Ceccherini Silberstein, F, Cinque, P, Cozzi Lepri, A, De Luca, A, Gervasoni, C, Girardi, E, Guaraldi, G, Lo Caputo, S, Madeddu, G, Maggiolo, F, Marchetti, G, Marcotullio, S, Monno, L, Murri, R, Puoti, M, Torti, C, Cicconi, P, Formenti, T, Galli, L, Lorenzini, P, Costantini, A, Giacometti, A, Riva, A, Carrisa, C, Lazzari, G, Verucchi, G, Kauffmann, R, Schippers, E, Minardi, C, Abeli, C, Quirino, T, Manconi, P, Piano, P, Falasca, K, Vecchiet, J, Segala, D, Sighinolfi, L, Alessandrini, A, Cassola, G, Mazzarello, G, Piscopo, R, Viscoli, G, Belvisi, V, Mastroianni, C, Caramma, I, Castelli, P, Chiodera, A, Alleman, M, Bouwhuis, J, Groeneveld, P, Bigoloni, A, Carenzi, L, Galli, A, Moioli, M, Piolini, R, Rizzardini, G, Rossotti, R, Salpietro, S, Spagnuolo, V, Zucchi, P, Bisio, L, Gori, A, Lapadula, G, Abrescia, N, Guida, M, Baldelli, F, Belfiori, B, Parruti, G, Ursini, T, Magnani, G, Ursitti, M, Acinapura, R, Capozzi, M, Gallo, L, Libertone, R, Nicastro, E, Tebano, G, Tozzi, V, d'Avino, A, Mura, M, Caramello, P, Orofino, G, Sciandra, M, Soetekouw, R, ten Kate, R, Manfrin, V, Pellizzer, G, Bernard, E, Caissotti, C, Cua, E, De Salvador Guillouet, F, Dellamonica, P, Dollet, K, Durant, J, Ferrando, S, Mondain Miton, V, Naqvi, A, Perbost, I, Pillet, S, Prouvost Keller, B, Pugliese, P, Rahelinirina, V, Roger, P, Barth, J, Bernasconi, E, Böni, J, Bucher, H, Burton Jeangros, C, Calmy, A, Cellerai, C, Dubs, R, Egger, M, Fehr, J, Flepp, M, Fux, C, Gorgievski, M, Günthard, H, Hasse, B, Hirsch, H, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Kind, C, Klimkait, T, Kovari, H, Martinetti, G, Martinez de Tejada, B, Müller, N, Nadal, D, Pantaleo, G, Rauch, A, Regenass, S, Rudin, C, Schmid, P, Schöni Affolter, F, Schüpbach, J, Schultze, D, Speck, R, Taffé, P, Telenti, A, Trkola, A, Vernazza, P, Yerly, S, von Wyl, V, Arend, S, Jolink, H, Kroon, F, de Boer, M, van Dissel, J, van Nieuwkoop, C, van den Broek, P, Pogany, K, den Hollander, J, Kortmann, W, van Twillert, G, Leyten, E, Vriesendorp, R, Kootstra, G, ten Napel, C, Blok, W, Brinkman, K, Frissen, P, Schouten, W, van den Berk, G, Brouwer, A, Juttmann, J, van Kasteren, M, Lettinga, K, Veenstra, J, Mulder, J, Smit, P, Weijer, S, van Gorp, E, Verhagen, D, van Eeden, A, Doedens, R, Scholvinck, E, Sprenger, H, Stek, C, van Assen, S, Dofferhoff, A, Keuter, M, Koopmans, P, de Groot, R, ter Hofstede, H, van der Flier, M, van der Ven, A, Arends, J, Ellerbroek, P, Hoepelman, A, Jaspers, C, Maarschalk Ellerbroek, L, Mudrikova, T, Oosterheert, J, Peters, E, Schneider, M, Wassenberg, M, van der Hilst, J, Bierman, W, Claessen, F, Danner, S, Perenboom, R, bij de Vaate, E, de Jong, E, de Vocht, J, van Agtmael, M, Geelen, S, Wolfs, T, Gisolf, E, Richter, J, van der Berg, C, Stegeman, A, van den Berge, M, Polée, M, van Houte, D, van Vonderen, M, Duits, A, Winkel, C, Chêne, G, Dupon, M, Fleury, H, Lacoste, D, Malvy, D, Mercié, P, Morlat, P, Pellegrin, I, Pellegrin, J, Thiébaut, R, Titier, K, Bruyand, M, Lawson Ayayi, S, Wittkop, L, Bernard, N, Bonnal, F, Caunègre, L, Cazanave, C, Ceccaldi, J, Chambon, D, Chossat, I, Courtaud, K, Dauchy, F, De Witte, S, Duffau, P, Dupont, A, Dutronc, H, Farbos, S, Gaboriau, V, Gemain, M, Gerard, Y, Greib, C, Hessamfar, M, Lafarie Castet, S, Lataste, P, Lazaro, E, Longy Boursier, M, Meraud, J, Monlun, E, Ochoa, A, Pistone, T, Ragnaud, J, Receveur, M, Roger Schmeltz, J, Tchamgoué, S, Thibaut, P, Vandenhende, M, Viallard, J, Moreau, J, P.e.l.l.e.g.r.i.n. , I, Lafon, M, Masquelier, B, Trimoulet, P, Breilh, D, Haramburu, F, Miremont Salamé, G, Blaizeau, M, D'Ivernois, C, Decoin, M, Delaune, J, Delveaux, S, Hanappier, C, Leleux, O, Sicard, X, Uwamaliya Nziyumvira, B, Leray, J, Palmer, G, Touchard, D, Baker, D, Bendall, C, Bloch, M, Carr, A, Cooper, D, Franic, T, Petoumenos, K, Vale, R, Edwards, S, Hoy, J, Moore, R, Nicholson, J, Roth, N, Watson, K, Chuah, J, Ngieng, M, Nolan, D, Skett, J, Cadafalch, J, Calvo, G, Codina, C, Del Cacho, E, Fuster, M, Mateu, S, Sirera, G, Vaqué, A, Clumeck, N, De Wit, S, Gennotte, A, Gerard, M, Kabeya, K, Konopnicki, D, Libois, A, Martin, C, Necsoi, C, Payen, M, Semaille, P, Van Laethem, Y, Bartsch, G, El Sadr, W, Neaton, J, Thompson, G, Wentworth, D, Luskin Hawk, R, Telzak, E, Cohn, D, Markowitz, N, Arduino, R, Mushatt, D, Friedland, G, Perez, G, Tedaldi, E, Fisher, E, Gordin, F, Crane, L, Sampson, J, Baxter, J, Fischer, A, Grint, D, Kjaer, J, Kowalska, J, Peters, L, Podlekareva, D, Reekie, J, Elias, C, Losso, M, Vetter, N, Zangerle, R, Karpov, I, Vassilenko, A, Mitsura, V, Suetnov, O, Colebunders, R, Vandekerckhove, L, Hadziosmanovic, V, Kostov, K, Begovac, J, Jilich, D, Machala, L, Sedlacek, D, Benfield, T, Kronborg, G, Larsen, M, Gerstoft, J, Hansen, A, Katzenstein, T, Skinhøj, P, Pedersen, C, Ostergaard, L, Zilmer, K, Gori, A., GORI, ANDREA, Groupement de Recherche et d'Etudes en Gestion à HEC (GREGH), Ecole des Hautes Etudes Commerciales (HEC Paris)-Centre National de la Recherche Scientifique (CNRS), Department of Pediatrics, Fairview-University Medical Center, Structures et propriétés d'architectures moléculaire (SPRAM - UMR 5819), Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Institut Nanosciences et Cryogénie (INAC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Observatoire des Micro et Nano Technologies (OMNT - UMS 2920), Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Université Paris 1 Panthéon-Sorbonne - UFR d'Économie (UP1 UFR02), Université Paris 1 Panthéon-Sorbonne (UP1), Laboratory, Royal GD [Deventer], Economics, Umeå University, Research Department of Infection and Population Health [London], University College of London [London] (UCL), Clinicum, Department of Medicine, Infektiosairauksien yksikkö, Worm, S, Bower, M, Reiss, P, Bonnet, F, Law, M, Fätkenheuer, G, d'Arminio Monforte, A, Abrams, D, Grulich, A, Fontas, E, Kirk, O, Furrer, H, Wit, S, Phillips, A, Lundgren, J, Sabin, C, Butcher, D, Delforge, M, Fanti, I, Franquet, X, Geffard, S, Gras, L, Helweg Larsen, J, Hillebregt, M, Kamara, D, Kjær, J, Krum, E, Mcmanus, H, Meidahl, P, Mocroft, A, Nielsen, J, Powderl, W, Rickenbach, M, Rode, R, Ryom, L, Salbøl Brandt, R, Schmidt Iversen, J, Shortman, N, Sjøl, A, Smith, C, Torres, F, Tverland, J, Wright, S, Zaheri, S, de Wolf, F, Smidt, J, Ristola, M, Katlama, C, Viard, J, Girard, P, Livrozet, J, Vanhems, P, Pradier, C, Dabis, F, Neau, D, Rockstroh, J, Schmidt, R, Degen, O, van Lunzen, J, Stellbrink, H, Staszewski, S, Bogner, J, Gargalianos, P, Kosmidis, J, Perdios, J, Xylomenos, G, Filandras, A, Karabatsaki, E, Panos, G, Sambatakou, H, Banhegyi, D, Mulcahy, F, Burke, M, Turner, D, Yust, I, Hassoun, G, Pollack, S, Maayan, S, Vella, S, Esposito, R, Mazeu, I, Mussini, C, Arici, C, Pristera, R, Gabbuti, A, Mazzotta, F, Lichtner, M, Vullo, V, Boer, K, Geerlings, S, Godfried, M, Kuijpers, T, Lange, J, Nellen, F, Pajkrt, D, Prins, J, Scherpbier, H, Vrouenraets, S, Wit, F, van Vugt, M, van der Meer, J, van der Poll, T, van der Valk, M, Chirianni, A, Gargiulo, M, Montesarchio, E, Antonucci, G, Narciso, P, Testa, A, Vlassi, C, Zaccarelli, M, Castagna, A, Gianotti, N, Lazzarin, A, Galli, M, Ridolfo, A, Rozentale, B, Zeltina, I, Chaplinskas, S, Hemmer, R, Staub, T, Bruun, J, Maeland, A, Ormaasen, V, Lowe, S, Oude Lashof, A, Schreij, G, Gasiorowski, J, Knysz, B, Bakowska, E, Horban, A, Flisiak, R, Grzeszczuk, A, Boron Kaczmarska, A, Parczewski, M, Pynka, M, Beniowski, M, Mularska, E, Trocha, H, Jablonowska, E, Malolepsza, E, Wojcik, K, Antunes, F, Caldeira, L, Doroana, M, Mansinho, K, Maltez, F, Bravenboer, B, Pronk, M, Duiculescu, D, Rakhmanova, A, Zakharova, N, Buzunova, S, Jevtovic, D, Mokráš, M, Staneková, D, Tomazic, J, González Lahoz, J, Labarga, P, Medrano, J, Soriano, V, Moreno, S, Rodriguez, J, Bravo, I, Clotet, B, Jou, A, Paredes, R, Puig, J, Tural, C, Gelinck, L, Nouwen, J, Rijnders, B, Schurink, C, Slobbe, L, Verbon, A, de Vries Sluijs, T, van der Ende, M, van der Feltz, M, Gatell, J, Miró, J, Domingo, P, Gutierrez, M, Mateo, G, Sambeat, M, Karlsson, A, Flamholc, L, Ledergerber, B, Weber, R, Cavassini, M, Francioli, P, Boffi, E, Hirschel, B, Battegay, M, Elzi, L, Chentsova, N, Kravchenko, E, Driessen, G, Hartwig, N, Frolov, V, Kutsyna, G, Servitskiy, S, Krasnov, M, Barton, S, Johnson, A, Mercey, D, Johnson, M, Murphy, M, Scullard, G, Weber, J, Fisher, M, Leen, C, Branger, J, Åkerlund, B, Morfeldt, L, S. u. n. d. s. t. r. ö. m., A, Thulin, G, Koppel, K, Ho̊kangård, C, Angarano, G, Antinori, A, Armignacco, O, Castelli, F, Cauda, R, Di Perri, G, Iardino, R, Ippolito, G, Moroni, M, Perno, C, Viale, P, Von Schlosser, F, Ammassari, A, Andreoni, M, Balotta, C, Bonfanti, P, Bonora, S, Borderi, M, Capobianchi, M, Ceccherini Silberstein, F, Cinque, P, Cozzi Lepri, A, De Luca, A, Gervasoni, C, Girardi, E, Gori, A, Guaraldi, G, Lo Caputo, S, Madeddu, G, Maggiolo, F, Marchetti, G, Marcotullio, S, Monno, L, Murri, R, Puoti, M, Torti, C, Cicconi, P, Formenti, T, Galli, L, Lorenzini, P, Costantini, A, Giacometti, A, Riva, A, Carrisa, C, Lazzari, G, Verucchi, G, Kauffmann, R, Schippers, E, Minardi, C, Abeli, C, Quirino, T, Manconi, P, Piano, P, Falasca, K, Vecchiet, J, Segala, D, Sighinolfi, L, Alessandrini, A, Cassola, G, Mazzarello, G, Piscopo, R, Viscoli, G, Belvisi, V, Mastroianni, C, Caramma, I, Castelli, P, Chiodera, A, Alleman, M, Bouwhuis, J, Groeneveld, P, Bigoloni, A, Carenzi, L, Galli, A, Moioli, M, Piolini, R, Rizzardini, G, Rossotti, R, Salpietro, S, Spagnuolo, V, Zucchi, P, Bisio, L, Lapadula, G, Abrescia, N, Guida, M, Baldelli, F, Belfiori, B, Parruti, G, Ursini, T, Magnani, G, Ursitti, M, Acinapura, R, Capozzi, M, Gallo, L, Libertone, R, Nicastro, E, Tebano, G, Tozzi, V, D'Avino, A, Mura, M, Caramello, P, Orofino, G, Sciandra, M, Soetekouw, R, ten Kate, R, Manfrin, V, Pellizzer, G, Bernard, E, Caissotti, C, Cua, E, De Salvador Guillouet, F, Dellamonica, P, Dollet, K, Durant, J, Ferrando, S, Mondain Miton, V, Naqvi, A, Perbost, I, Pillet, S, Prouvost Keller, B, Pugliese, P, Rahelinirina, V, Roger, P, Barth, J, Bernasconi, E, Böni, J, Bucher, H, Burton Jeangros, C, Calmy, A, Cellerai, C, Dubs, R, Egger, M, Fehr, J, Flepp, M, Fux, C, Gorgievski, M, Günthard, H, Hasse, B, Hirsch, H, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Kind, C, Klimkait, T, Kovari, H, Martinetti, G, Martinez de Tejada, B, Müller, N, Nadal, D, Pantaleo, G, Rauch, A, Regenass, S, Rudin, C, Schmid, P, Schöni Affolter, F, Schüpbach, J, Schultze, D, Speck, R, Taffé, P, Telenti, A, Trkola, A, Vernazza, P, Yerly, S, von Wyl, V, Arend, S, Jolink, H, Kroon, F, de Boer, M, van Dissel, J, van Nieuwkoop, C, van den Broek, P, Pogany, K, den Hollander, J, Kortmann, W, van Twillert, G, Leyten, E, Vriesendorp, R, Kootstra, G, ten Napel, C, Blok, W, Brinkman, K, Frissen, P, Schouten, W, van den Berk, G, Brouwer, A, Juttmann, J, van Kasteren, M, Lettinga, K, Veenstra, J, Mulder, J, Smit, P, Weijer, S, van Gorp, E, Verhagen, D, van Eeden, A, Doedens, R, Scholvinck, E, Sprenger, H, Stek, C, van Assen, S, Dofferhoff, A, Keuter, M, Koopmans, P, de Groot, R, ter Hofstede, H, van der Flier, M, van der Ven, A, Arends, J, Ellerbroek, P, Hoepelman, A, Jaspers, C, Maarschalk Ellerbroek, L, Mudrikova, T, Oosterheert, J, Peters, E, Schneider, M, Wassenberg, M, van der Hilst, J, Bierman, W, Claessen, F, Danner, S, Perenboom, R, bij de Vaate, E, de Jong, E, de Vocht, J, van Agtmael, M, Geelen, S, Wolfs, T, Gisolf, E, Richter, J, van der Berg, C, Stegeman, A, van den Berge, M, Polée, M, van Houte, D, van Vonderen, M, Duits, A, Winkel, C, Chêne, G, Dupon, M, Fleury, H, Lacoste, D, Malvy, D, Mercié, P, Morlat, P, Pellegrin, I, Pellegrin, J, Thiébaut, R, Titier, K, Bruyand, M, Lawson Ayayi, S, Wittkop, L, Bernard, N, Bonnal, F, Caunègre, L, Cazanave, C, Ceccaldi, J, Chambon, D, Chossat, I, Courtaud, K, Dauchy, F, De Witte, S, Duffau, P, Dupont, A, Dutronc, H, Farbos, S, Gaboriau, V, Gemain, M, Gerard, Y, Greib, C, Hessamfar, M, Lafarie Castet, S, Lataste, P, Lazaro, E, Longy Boursier, M, Meraud, J, Monlun, E, Ochoa, A, Pistone, T, Ragnaud, J, Receveur, M, Roger Schmeltz, J, Tchamgoué, S, Thibaut, P, Vandenhende, M, Viallard, J, Moreau, J, P. e. l. l. e. g. r. i. n., I, Lafon, M, Masquelier, B, Trimoulet, P, Breilh, D, Haramburu, F, Miremont Salamé, G, Blaizeau, M, D'Ivernois, C, Decoin, M, Delaune, J, Delveaux, S, Hanappier, C, Leleux, O, Sicard, X, Uwamaliya Nziyumvira, B, Leray, J, Palmer, G, Touchard, D, Baker, D, Bendall, C, Bloch, M, Carr, A, Cooper, D, Franic, T, Petoumenos, K, Vale, R, Edwards, S, Hoy, J, Moore, R, Nicholson, J, Roth, N, Watson, K, Chuah, J, Ngieng, M, Nolan, D, Skett, J, Cadafalch, J, Calvo, G, Codina, C, Del Cacho, E, Fuster, M, Mateu, S, Sirera, G, Vaqué, A, Clumeck, N, De Wit, S, Gennotte, A, Gerard, M, Kabeya, K, Konopnicki, D, Libois, A, Martin, C, Necsoi, C, Payen, M, Semaille, P, Van Laethem, Y, Bartsch, G, El Sadr, W, Neaton, J, Thompson, G, Wentworth, D, Luskin Hawk, R, Telzak, E, Cohn, D, Markowitz, N, Arduino, R, Mushatt, D, Friedland, G, Perez, G, Tedaldi, E, Fisher, E, Gordin, F, Crane, L, Sampson, J, Baxter, J, Fischer, A, Grint, D, Kjaer, J, Kowalska, J, Peters, L, Podlekareva, D, Reekie, J, Elias, C, Losso, M, Vetter, N, Zangerle, R, Karpov, I, Vassilenko, A, Mitsura, V, Suetnov, O, Colebunders, R, Vandekerckhove, L, Hadziosmanovic, V, Kostov, K, Begovac, J, Jilich, D, Machala, L, Sedlacek, D, Benfield, T, Kronborg, G, Larsen, M, Gerstoft, J, Hansen, A, Katzenstein, T, Skinhøj, P, Pedersen, C, Ostergaard, L, Zilmer, K, Internal medicine, Pediatric surgery, Plastic, Reconstructive and Hand Surgery, CCA - Innovative therapy, IOO, Worm, Signe W., Bower, Mark, Reiss, Peter, Bonnet, Fabrice, Law, Matthew, Fã¤tkenheuer, Gerd, D'arminio Monforte, Antonella, Abrams, Donald I., Grulich, Andrew, Fontas, Eric, Kirk, Ole, Furrer, Hansjakob, Wit, Stephane D., Phillips, Andrew, Lundgren, Jens D., Sabin, Caroline A., D:A:D Study, Group, Experimental Psychology, Groningen Research Institute for Asthma and COPD (GRIAC), Amsterdam institute for Infection and Immunity, Amsterdam Public Health, Global Health, Other departments, Infectious diseases, Paediatric Infectious Diseases / Rheumatology / Immunology, Other Research, Obstetrics and Gynaecology, General Internal Medicine, Center of Experimental and Molecular Medicine, Medical Microbiology and Infection Prevention, Institut Nanosciences et Cryogénie (INAC), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, Kaplan Meier method, proportional hazards model, SWISS HIV COHORT, HIV Infections, 0302 clinical medicine, 1108 Medical Microbiology, cancer diagnosis, Prospective Studies, Pathologie maladies infectieuses, cancer survival, ComputingMilieux_MISCELLANEOUS, IMMUNODEFICIENCY, Incidence, Sciences bio-médicales et agricoles, cohort analysis, Prognosis, 3. Good health, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, D:A:D Study Group, risk factor, 030220 oncology & carcinogenesis, Cohort, Cohort study, prospective study, Human, medicine.medical_specialty, Prognosi, HIV, Non-AIDS defining cancers, Trends, Adult, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasms, Infectious Diseases, non AIDS defining cancer, Microbiology, cancer prognosis, 03 medical and health sciences, death, Anal cancer, Risk factor, Proportional hazards model, HIV Infections -- drug therapy -- mortality, Anti-HIV Agent, Anti-HIV Agents/therapeutic use, Antiretroviral Therapy, HIV Infections/drug therapy/ mortality, medicine.disease, major clinical study, mortality, Prospective Studie, age, Neoplasms -- mortality, observational study, cancer incidence, anus cancer, gender, Trend, Medicine and Health Sciences, HIV Infection, 030212 general & internal medicine, Prospective cohort study, survival prediction, RISK, INFECTED PATIENTS, ACTIVE ANTIRETROVIRAL THERAPY, Incidence (epidemiology), article, Human immunodeficiency virus infected patient, ANAL CANCER, Non-AIDS defining cancer, Anti-HIV Agents -- therapeutic use, ethnicity, 0605 Microbiology, Research Article, Hodgkin disease, UNITED-STATES, 610 Medicine & health, smoking, NO, MALIGNANCIES, Internal medicine, mental disorders, medicine, follow up, Highly Active, controlled study, Lung cancer, HODGKINS-DISEASE, disseminated cancer, business.industry, 1103 Clinical Sciences, BONE-MARROW-TRANSPLANTATION, Surgery, lung cancer, 3121 General medicine, internal medicine and other clinical medicine, Neoplasm, business
Abstract

Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004-2010, and described subsequent mortality and predictors of these., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2013

14. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir

Author

HIV Cohort Study, Switzerland, von Wyl, V, Yerly, S, Klimkait, T, Böni, J, Bürgisser, P, Battegay, M, Bernasconi, E, Cavassini, M, Furrer, H, Hirschel, B, Vernazza, P L, Rickenbach, M, Ledergerber, B, Guenthard, H F, University of Zurich, and von Wyl, V

Subjects
10028 Institute of Medical Virology, 10234 Clinic for Infectious Diseases, 570 Life sciences, biology, 610 Medicine & health, 2725 Infectious Diseases, 2726 Microbiology (medical)
Published
2008

17. The incidence of AIDS-defining illnesses at a current CD4 count ≥200 cells/μL in the post-combination antiretroviral therapy era

Author

Mocroft, A., Furrer, H. J., Miro, J. M., Reiss, P., Mussini, C., Kirk, O., Abgrall, S., Ayayi, S., Bartmeyer, B., Braun, D., Castagna, A., d'Arminio Monforte, A., Gazzard, B., Gutierrez, F., Hurtado, I., Jansen, K., Meyer, L., Munoz, P., Obel, N., Soler Palacin, P., Papadopoulos, A., Raffi, F., Ramos, J. T., Rockstroh, J. K., Salmon, D., Torti, Carlo, Warszawski, J., de Wit, S., Zangerle, R., Fabre Colin, C., Kjaer, J., Chene, G., Grarup, J., Lundgren, J. D., Furrer, H., Rockstroh, J., Lundgren, J., Miiro, J., Palacin, P. S., Torti, C., Ramos, J., Judd, A., Haerry, D., Weller, I., Casabona, J., Costagliola, D., Battegay, M., Prins, M., de Wolf, F., Colin, C., Schwimmer, C., Touzeau, G., Campbell, M., Bohlius, J., Bouteloup, V., Bucher, H., Cozzi Lepri, A., Dabis, F., Dorrucci, M., Egger, M., Engsig, F., Lambotte, O., Lewden, C., Lodwick, R., Matheron, S., Miro, J., Paredes, R., Phillips, A., Puoti, M., Reekie, J., Sabin, C., Scherrer, A., Smit, C., Sterne, J., Thiebaut, R., Thorne, C., von Wyl, V., Wittkop, L., Young, J., Mocroft, A., Furrer, H. J., Miro, J. M., Reiss, P., Mussini, C., Kirk, O., Abgrall, S., Ayayi, S., Bartmeyer, B., Braun, D., Castagna, A., D'Arminio Monforte, A., Gazzard, B., Gutierrez, F., Hurtado, I., Jansen, K., Meyer, L., Munoz, P., Obel, N., Soler-Palacin, P., Papadopoulos, A., Raffi, F., Ramos, J. T., Rockstroh, J. K., Salmon, D., Torti, C., Warszawski, J., De Wit, S., Zangerle, R., Fabre-Colin, C., Kjaer, J., Chene, G., Grarup, J., Lundgren, J. D., AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Global Health, Other departments, Infectious diseases, University of Zurich, and Mocroft, A

Subjects
Microbiology (medical), Adult, CD4-Positive T-Lymphocytes, Male, medicine.medical_specialty, Virologic suppression, AIDS defining illnesses, Human immunodeficiency virus (HIV), 610 Medicine & health, HIV Infections, Rate ratio, medicine.disease_cause, 2726 Microbiology (medical), 10234 Clinic for Infectious Diseases, Cohort Studies, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, Acquired immunodeficiency syndrome (AIDS), 360 Social problems & social services, Internal medicine, medicine, CART, Humans, 030212 general & internal medicine, Poisson regression, Poisson Distribution, 0303 health sciences, 030306 microbiology, business.industry, Incidence (epidemiology), Incidence, CD4, cART, immune reconstitution, virologic suppression, Anti-Retroviral Agents, CD4 Lymphocyte Count, Europe, Female, 2725 Infectious Diseases, Immune reconstitution, medicine.disease, Antiretroviral therapy, Confidence interval, 3. Good health, Infectious Diseases, Immunology, symbols, business, Viral load
Abstract

Background. Few studies consider the incidence of individual AIDS-defining illnesses (ADIs) at higher CD4 counts, relevant on a population level for monitoring and resource allocation. Methods. Individuals from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) aged ≥14 years with ≥1 CD4 count of ≥200 μL between 1998 and 2010 were included. Incidence rates (per 1000 personyears of follow-up [PYFU]) were calculated for each ADI within different CD4 strata; Poisson regression, using generalized estimating equations and robust standard errors, was used to model rates of ADIs with current CD4 ≥500/μL. Results. A total of 12 135 ADIs occurred at a CD4 count of ≥200 cells/μL among 207 539 persons with 1 154 803 PYFU. Incidence rates declined from 20.5 per 1000 PYFU (95% confidence interval [CI], 20.0-21.1 per 1000 PYFU) with current CD4 200-349 cells/μL to 4.1 per 1000 PYFU (95% CI, 3.6-4.6 per 1000 PYFU) with current CD4 ≥ 1000 cells/μL. Persons with a current CD4 of 500-749 cells/μL had a significantly higher rate of ADIs (adjusted incidence rate ratio [aIRR], 1.20; 95% CI, 1.10-1.32), whereas those with a current CD4 of ≥1000 cells/μL had a similar rate (aIRR, 0.92; 95% CI, .79-1.07), compared to a current CD4 of 750-999 cells/μL. Results were consistent in persons with high or low viral load. Findings were stronger for malignant ADIs (aIRR, 1.52; 95% CI, 1.25-1.86) than for nonmalignant ADIs (aIRR, 1.12; 95% CI, 1.01-1.25), comparing persons with a current CD4 of 500-749 cells/μL to 750-999 cells/μL. Discussion. The incidence of ADIs was higher in individuals with a current CD4 count of 500-749 cells/μL compared to those with a CD4 count of 750-999 cells/μL, but did not decrease further at higher CD4 counts. Results were similar in patients virologically suppressed on combination antiretroviral therapy, suggesting that immune reconstitution is not complete until the CD4 increases to >750 cells/μL. © The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.

Published
2013

18. CD4 cell count and the risk of AIDS or death in HIV-Infected adults oncombination antiretroviral therapy with a suppressed viral load: a longitudinalcohort study from COHERE

Author

Collaborators: Young J, Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe in E. u. r. o. C. o. o. r. d., Psichogiou, M, Meyer, L, Ayayi, S, Grabar, S, Raffi, F, Reiss, P, Gazzard, B, Sharland, M, Gutierrez, F, Obel, N, Kirk, O, Miro, Jm, Furrer, H, Castagna, A, De Wit, S, Muñoz, J, Kjær, J, Colin, C, Grarup, J, Chêne, G, Bucher, H, Miro, J, Zangerle, R, Antoniadou, A, Ghosn, J, Morlat, P, Le Moing, V, Fisher, M, Mocroft, A, Stephan, C, Girardi, E, Torti, Carlo, Mussini, C, Galli, L, Ledergerber, B, Teira, R, Touloumi, G, Warszawski, J, Dabis, F, Krause, Mm, Leport, C, de Wolf, F, Prins, M, Bücher, H, Sabin, C, Gibb, D, Fätkenheuer, G, Del Amo, J, Thorne, C, Pérez Hoyos, S, Noguera Julian, A, Antinori, A, d'Arminio Monforte, A, Brockmeyer, N, Ramos, J, Battegay, M, Rauch, A, Tookey, P, Casabona, J, de Wit, S, Goetghebuer, T, Torti, C, Garrido, M, Haerry, D, Weller, I, Costagliola, D, Schwimmer, C, Touzeau, G, Paulsen, M, Bohlius, J, Bouteloup, V, Cozzi Lepri, A, Dorrucci, M, Egger, M, Engsig, F, Lambotte, O, Lewden, C, Lodwick, R, Matheron, S, Paredes, R, Phillips, A, Puoti, M, Reekie, J, Scherrer, A, Smit, C, Sterne, J, Thiebaut, R, von Wyl, V, Wittkop, L, and Young, J.

Published
2012

19. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe

Author

Pursuing Later Treatment Options II project team, Collaboration of Observational HIV Epidemiological Research Europe Group, Nakagawa, F, Lodwick, R, Costagliola, D, van Sighem, A, Torti, Carlo, Podzamczer, D, Mocroft, A, Ledergerber, B, Dorrucci, M, Cozzi Lepri, A, Jansen, K, Masquelier, B, García, F, De Wit, S, Stephan, C, Obel, N, Fätkenhaeuer, G, Castagna, A, Sambatakou, H, Mussini, C, Ghosn, J, Zangerle, R, Duval, X, Meyer, L, Perez Hoyos, S, Fabre Colin, C, Kjaer, J, Chene, G, Grarup, J, Collaborators: Castagna A, Phillips A., De Luca, A, de Wolf, F, Fätkenheuer, G, Günthard, H, Jørgensen, L, Judd, A, Lo Caputo, S, Noguera Julian, A, Paraskevis, D, Paredes, R, Pérez Hoyos, S, Phillips, A, Pillay, D, Ramos, Jt, Tookey, Pa, Torti, C, Touloumi, G, Warsawski, J, Warszawski, J, Dabis, F, Krause, Mm, Leport, C, Reiss, P, Prins, M, Bücher, H, Sabin, C, Gibb, D, Del Amo, J, Thorne, C, Kirk, O, Antinori, A, Monforte, Ad, Brockmeyer, N, Ramos, J, Battegay, M, Rauch, A, Tookey, P, Casabona, J, Miró, Jm, de Wit, S, Goetghebuer, T, Teira, R, Garrido, M, Haerry, D, Weller, I, d'Arminio Monforte, A, Colin, C, Schwimmer, C, Touzeau, G, Paulsen, M, Bohlius, J, Bouteloup, V, Bucher, H, Egger, M, Engsig, F, Furrer, H, Lambotte, O, Lewden, C, Matheron, S, Miro, J, Puoti, M, Reekie, J, Scherrer, A, Smit, C, Sterne, J, Thiebaut, R, von Wyl, V, Wittkop, L, and Youn, J.

Published
2012

20. Impact of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy – a European multi-cohort study – The EuroCoord-CHAIN joint project

Author

Wittkop, L, Günthard, Hf, de Wolf, F, Dunn, D, Cozzi Lepri, A, de Luca, A, Kücherer, C, Obel, N, von Wyl, V, Masquelier, B, Stephan, C, Torti, Carlo, Antinori, A, García, F, Judd, A, Porter, K, Thiébaut, R, Castro, H, van Sighem AI, Colin, C, Kjaer, J, Lundgren, Jd, Paredes, R, Pozniak, A, Clotet, B, Phillips, A, Pillay, D, Chêne, G, and for the EuroCoord CHAIN study group

Published
2011

21. B cells from HIV-infected patients with primary central nervous system lymphoma display an activated phenotype and have a blunted TNF-α response to TLR9 triggering

Author

Audigé, A, Schlaepfer, E, von Wyl, V, Miller, R C, Vernazza, P, Nadal, D, Speck, R F, and University of Zurich

Subjects
10234 Clinic for Infectious Diseases, 2403 Immunology, Infectious Diseases, 10036 Medical Clinic, Virology, Immunology, 2406 Virology, 610 Medicine & health, 2725 Infectious Diseases
Published
2010
Full Text
View/download PDF

22. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types

Author

von Wyl, V, Yerly, S, Böni, J, Bürgisser, P, Klimkait, T, Battegay, M, Furrer, H, Telenti, A, Hirschel, B, Vernazza, P L, Bernasconi, E, Rickenbach, M, Perrin, L, Ledergerber, B, Günthard, H F, Swiss HIV Cohort Study, University of Zurich, and Günthard, H F

Subjects
10028 Institute of Medical Virology, 2724 Internal Medicine, 570 Life sciences, biology, 610 Medicine & health
Published
2007

23. The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland.

Author

von Wyl V, Kouyos RD, Yerly S, Böni J, Shah C, Bürgisser P, Klimkait T, Weber R, Hirschel B, Cavassini M, Staehelin C, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Bonhoeffer S, Günthard HF, and Swiss HIV Cohort Study

Abstract

BACKGROUND: By analyzing human immunodeficiency virus type 1 (HIV-1) pol sequences from the Swiss HIV Cohort Study (SHCS), we explored whether the prevalence of non-B subtypes reflects domestic transmission or migration patterns. METHODS: Swiss non-B sequences and sequences collected abroad were pooled to construct maximum likelihood trees, which were analyzed for Swiss-specific subepidemics, (subtrees including >=80% Swiss sequences, bootstrap >70%; macroscale analysis) or evidence for domestic transmission (sequence pairs with genetic distance <1.5%, bootstrap >=98%; microscale analysis). RESULTS: Of 8287 SHCS participants, 1732 (21%) were infected with non-B subtypes, of which A (n = 328), C (n = 272), CRF01_AE (n = 258), and CRF02_AG (n = 285) were studied further. The macroscale analysis revealed that 21% (A), 16% (C), 24% (CRF01_AE), and 28% (CRF02_AG) belonged to Swiss-specific subepidemics. The microscale analysis identified 26 possible transmission pairs: 3 (12%) including only homosexual Swiss men of white ethnicity; 3 (12%) including homosexual white men from Switzerland and partners from foreign countries; and 10 (38%) involving heterosexual white Swiss men and females of different nationality and predominantly nonwhite ethnicity. CONCLUSIONS: Of all non-B infections diagnosed in Switzerland, <25% could be prevented by domestic interventions. Awareness should be raised among immigrants and Swiss individuals with partners from high prevalence countries to contain the spread of non-B subtypes. [ABSTRACT FROM AUTHOR]

Published
2011

24. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

Author

Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, and Muga R

Abstract

Background: Most clinical guidelines recommend that AIDS-free, HIV-infected persons with CD4 cell counts below 0.350 × 10(9) cells/L initiate combined antiretroviral therapy (cART), but the optimal CD4 cell count at which cART should be initiated remains a matter of debate.Objective: To identify the optimal CD4 cell count at which cART should be initiated.Design: Prospective observational data from the HIV-CAUSAL Collaboration and dynamic marginal structural models were used to compare cART initiation strategies for CD4 thresholds between 0.200 and 0.500 × 10(9) cells/L.Setting: HIV clinics in Europe and the Veterans Health Administration system in the United States.Patients: 20, 971 HIV-infected, therapy-naive persons with baseline CD4 cell counts at or above 0.500 × 10(9) cells/L and no previous AIDS-defining illnesses, of whom 8392 had a CD4 cell count that decreased into the range of 0.200 to 0.499 × 10(9) cells/L and were included in the analysis.Measurements: Hazard ratios and survival proportions for all-cause mortality and a combined end point of AIDS-defining illness or death.Results: Compared with initiating cART at the CD4 cell count threshold of 0.500 × 10(9) cells/L, the mortality hazard ratio was 1.01 (95% CI, 0.84 to 1.22) for the 0.350 threshold and 1.20 (CI, 0.97 to 1.48) for the 0.200 threshold. The corresponding hazard ratios were 1.38 (CI, 1.23 to 1.56) and 1.90 (CI, 1.67 to 2.15), respectively, for the combined end point of AIDS-defining illness or death.Limitations: CD4 cell count at cART initiation was not randomized. Residual confounding may exist.Conclusion: Initiation of cART at a threshold CD4 count of 0.500 × 10(9) cells/L increases AIDS-free survival. However, mortality did not vary substantially with the use of CD4 thresholds between 0.300 and 0.500 × 10(9) cells/L. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

25. Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study.

Author

Scherrer AU, von Wyl V, Joos B, Klimkait T, Bürgisser P, Yerly S, Böni J, Ledergerber B, Günthard HF, Swiss HIV Cohort Study, Scherrer, Alexandra U, von Wyl, Viktor, Joos, Beda, Klimkait, Thomas, Bürgisser, Philippe, Yerly, Sabine, Böni, Jürg, Ledergerber, Bruno, and Günthard, Huldrych F

Abstract

The 69 insertion and Q151M mutations are multi-nucleoside/nucleotide resistance mutations (MNR). The prevalence among 4078 antiretroviral therapy (ART)-experienced individuals was <1.3%. Combined ART fully prevented MNR in subtype B infections. Case-control studies were performed to identify risk factors. Control subjects were patients with ≥ 3 thymidine-analogue mutations. The 69 insertion study (27 control subjects, 14 case patients) identified didanosine exposure as a risk (odds ratio, 5.0 per year; P = .019), whereas the Q151M study (which included 44 control subjects and 25 case patients) detected no associations. Following detection, individuals with Q151M tended to have lower suppression rates and higher mortality rates, relative to control subjects. Additional studies are needed to verify these findings in non-subtype B infections. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

35. Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study

Author

Martinetti Gladys, Vernazza Pietro, Hirschel Bernard, Fux Christoph A, Cavassini Matthias, Bürgisser Philippe, Yerly Sabine, Böni Jürg, von Wyl Viktor, Hirsch Hans H, Hamy François, Louvel Séverine, Glass Tracy R, Fehr Jan, Bernasconi Enos, Günthard Huldrych F, Battegay Manuel, Bucher Heiner C, and Klimkait Thomas

Subjects
Medicine
Abstract

Abstract Background Replicative phenotypic HIV resistance testing (rPRT) uses recombinant infectious virus to measure viral replication in the presence of antiretroviral drugs. Due to its high sensitivity of detection of viral minorities and its dissecting power for complex viral resistance patterns and mixed virus populations rPRT might help to improve HIV resistance diagnostics, particularly for patients with multiple drug failures. The aim was to investigate whether the addition of rPRT to genotypic resistance testing (GRT) compared to GRT alone is beneficial for obtaining a virological response in heavily pre-treated HIV-infected patients. Methods Patients with resistance tests between 2002 and 2006 were followed within the Swiss HIV Cohort Study (SHCS). We assessed patients' virological success after their antiretroviral therapy was switched following resistance testing. Multilevel logistic regression models with SHCS centre as a random effect were used to investigate the association between the type of resistance test and virological response (HIV-1 RNA Results Of 1158 individuals with resistance tests 221 with GRT+rPRT and 937 with GRT were eligible for analysis. Overall virological response rates were 85.1% for GRT+rPRT and 81.4% for GRT. In the subgroup of patients with >2 previous failures, the odds ratio (OR) for virological response of GRT+rPRT compared to GRT was 1.45 (95% CI 1.00-2.09). Multivariate analyses indicate a significant improvement with GRT+rPRT compared to GRT alone (OR 1.68, 95% CI 1.31-2.15). Conclusions In heavily pre-treated patients rPRT-based resistance information adds benefit, contributing to a higher rate of treatment success.

Published
2011
Full Text
View/download PDF

36. Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy

Author

Weber Rainer, Ackermann Martina, von Wyl Viktor, Hafner Roland, Kaiser Philipp, Niederöst Barbara, Joos Beda, Fischer Marek, and Günthard Huldrych F

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Mathematical models based on kinetics of HIV-1 plasma viremia after initiation of combination antiretroviral therapy (cART) inferred HIV-infected cells to decay exponentially with constant rates correlated to their strength of virus production. To further define in vivo decay kinetics of HIV-1 infected cells experimentally, we assessed infected cell-classes of distinct viral transcriptional activity in peripheral blood mononuclear cells (PBMC) of five patients during 1 year after initiation of cART Results In a novel analytical approach patient-matched PCR for unspliced and multiply spliced viral RNAs was combined with limiting dilution analysis at the single cell level. This revealed that HIV-RNA+ PBMC can be stratified into four distinct viral transcriptional classes. Two overlapping cell-classes of high viral transcriptional activity, suggestive of a virion producing phenotype, rapidly declined to undetectable levels. Two cell classes expressing HIV-RNA at low and intermediate levels, presumably insufficient for virus production and occurring at frequencies exceeding those of productively infected cells matched definitions of HIV-latency. These cells persisted during cART. Nevertheless, during the first four weeks of therapy their kinetics resembled that of productively infected cells. Conclusion We have observed biphasic decays of latently HIV-infected cells of low and intermediate viral transcriptional activity with marked decreases in cell numbers shortly after initiation of therapy and complete persistence in later phases. A similar decay pattern was shared by cells with greatly enhanced viral transcriptional activity which showed a certain grade of levelling off before their disappearance. Thus it is conceivable that turnover/decay rates of HIV-infected PBMC may be intrinsically variable. In particular they might be accelerated by HIV-induced activation and reactivation of the viral life cycle and slowed down by the disappearance of such feedback-loops after initiation of cART.

Published
2008
Full Text
View/download PDF

37. Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations

Author

von Wyl, Viktor, Yerly, Sabine, Böni, Jürg, Shah, Cyril, Cellerai, Cristina, Klimkait, Thomas, Battegay, Manuel, Bernasconi, Enos, Cavassini, Matthias, Furrer, Hansjakob, Hirschel, Bernard, Vernazza, Pietro L, Ledergerber, Bruno, Günthard, Huldrych F, Swiss HIV Cohort, Study, Swiss HIV Cohort Study, Barth, J., Battegay, M., Bernasconi, E., Böni, J., Bucher, HC., Bürgisser, P., Burton-Jeangros, C., Calmy, A., Cavassini, M., Cellerai, C., Egger, M., Elzi, L., Fehr, J., Flepp, M., Francioli, P., Furrer, H., Fux, CA., Gorgievski, M., Günthard, H., Hasse, B., Hirsch, HH., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Müller, N., Nadal, D., Pantaleo, C., Rauch, A., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schöni-Affolter, F., Schüpbach, J., Speck, R., Taffé, P., Telenti, A., Trkola, A., Vernazza, P., von Wyl, V., Weber, R., Yerly, S., University of Zurich, and von Wyl, V

Subjects
Oncology, 10028 Institute of Medical Virology, Male, Human immunodeficiency virus (HIV), HIV Infections, Drug resistance, medicine.disease_cause, 2726 Microbiology (medical), 10234 Clinic for Infectious Diseases, chemistry.chemical_compound, 0302 clinical medicine, 030212 general & internal medicine, ddc:616, 0303 health sciences, Incidence, Lamivudine, virus diseases, Lopinavir, Middle Aged, Viral Load, 3. Good health, HIV-1/classification/drug effects/genetics/isolation & purification, Infectious Diseases, Treatment Outcome, Female, medicine.drug, Microbiology (medical), Adult, medicine.medical_specialty, Efavirenz, Genotype, Anti-HIV Agents, 610 Medicine & health, Emtricitabine, 03 medical and health sciences, Zidovudine, Anti-HIV Agents/administration & dosage, Anti-HIV Agents/pharmacology, Drug Resistance, Viral, HIV Infections/drug therapy, HIV Infections/virology, HIV-1/classification, HIV-1/drug effects, Humans, Internal medicine, medicine, Antiretroviral treatment, HIV Infections/drug therapy/virology, 030306 microbiology, business.industry, Anti-HIV Agents/administration & dosage/pharmacology, 2725 Infectious Diseases, chemistry, Immunology, HIV-1, 570 Life sciences, biology, business
Abstract

BACKGROUND: Estimates of drug resistance incidence to modern first-line combination antiretroviral therapies against human immunodeficiency virus (HIV) type 1 are complicated by limited availability of genotypic drug resistance tests (GRTs) and uncertain timing of resistance emergence. METHODS: Five first-line combinations were studied (all paired with lamivudine or emtricitabine): efavirenz (EFV) plus zidovudine (AZT) (n = 524); EFV plus tenofovir (TDF) (n = 615); lopinavir (LPV) plus AZT (n = 573); LPV plus TDF (n = 301); and ritonavir-boosted atazanavir (ATZ/r) plus TDF (n = 250). Virological treatment outcomes were classified into 3 risk strata for emergence of resistance, based on whether undetectable HIV RNA levels were maintained during therapy and, if not, whether viral loads were >500 copies/mL during treatment. Probabilities for presence of resistance mutations were estimated from GRTs (n = 2876) according to risk stratum and therapy received at time of testing. On the basis of these data, events of resistance emergence were imputed for each individual and were assessed using survival analysis. Imputation was repeated 100 times, and results were summarized by median values (2.5th-97.5th percentile range). RESULTS: Six years after treatment initiation, EFV plus AZT showed the highest cumulative resistance incidence (16%) of all regimens (500 copies/mL). CONCLUSIONS: The inclusion of TDF instead of AZT and ATZ/r was correlated with lower rates of resistance emergence, most likely because of improved tolerability and pharmacokinetics resulting from a once-daily dosage.

Published
2012

38. Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland

Author

Erin A. West, Anja Frei, Idris Guessous, Thomas Vermes, Silvia Stringhini, Daniel H. Paris, Daniela Anker, Adina Mihaela Epure, Ania Wisniak, Rebecca Amati, Luca Crivelli, Nicolas Rodondi, Jan Fehr, Milo A. Puhan, Audrey Butty, Medea Imboden, Laurent Kaufmann, Emiliano Albanese, Arnaud Chiolero, Gisela Michel, Valérie D'Acremont, Nicole Probst-Hensch, Christian R Kahlert, Murielle Bochud, Irène Frank, Nicolai Mösli, Stéphane Cullati, Fabian Vollrath, Philipp Kohler, Aude Richard, Semira Gonseth, Antoine Flahault, Luc Fornerod, Azman, Andrew, Baysson, Hélène, Collombet, Prune, Dibner, Yaron, Kaiser, Laurent, Petrovic, Dusan, Picazio, Attilio, Portier, Jane, Pugin, Caroline, University of Zurich, Puhan, Milo A, Corona Immunitas Research Group, Albanese, E., Amati, R., Amendola, A., Anker, D., Annoni, A.M., Azman, A., Bally, F., Balmer, B., Baysson, H., Berthod, D., Blankenberger, J., Bochud, M., Bodenmann, P., Bopp, M., Butty, A., Camerini, A.L., Cappeli, C., Carmelli, C., Chiolero, A., Collombet, P., Corna, L., Crawford, J., Crivelli, L., Cullati, S., Cusini, A., D'Acremont, V., De Pietro, C., Deschamps, A., Droz, S., Dumoulin, A., Duperrex, O., Dupraz, J., Egger, M., Engler, N., Epure, A.M., Estoppey, S., Fadda, M., Faivre, V., Fehr, J., Felappi, A., Fiordelli, M., Flahault, A., Fornerod, L., Fragoso Corti, C., Frangville, M., Frank, I., Franscella, G., Frei, A., Gille, D., Michel, G., Gonseth Nusslé, S., Gouzowski, A., Guessous, I., Guggisberg, J., Günthard, H., Gutzwiller, F., Incici, L., Jendly, E., Jung, R., Kahlert, C., Kaiser, L., Kaufmann, L., Kaufmann, M., Kessler, S., Kohler, P., Kriemler, S., Lenoir, L., Levati, S., Maeschli, B., Magnin, J.L., Masserey, E., Morese, R., Mösli, N., Noël, N., Orhant, M., Pasquier, J., Pennacchio, F., Petrovic, D., Pfister, S., Picazio, A., Prandi, C., Piumatti, G., Portier, J., Probst-Hensch, N., Pugin, C., Puhan, M., Radtke, T., Richard, A., Robert, C.F., Rodondi, P.Y., Rodondi, N., Salberg, E., Sanchis Zozaya, J., Schlüter, V., Schneider, V., Steiner-Dubuis, A., Stringhini, S., Sumer, J., Tall, I., Thabard, J., Tonolla, M., Troillet, N., Ulyte, A., Vassaux, S., Vermes, T., Vollrath, F., von Wyl, V., West, E., Wisniak, A., Zaballa, M.E., and Zuppinger, C.

Subjects
Research design, Health (social science), Ethnic group, 030204 cardiovascular system & hematology, Socioeconomic differences, Antibodies, Viral, Viral/blood, ddc:616.89, 0302 clinical medicine, Seroepidemiologic Studies, Pandemic, Epidemiology, Prevalence, Ethnicity, 030212 general & internal medicine, Serosurvey, Child, 610 Medicine & health, COVID-19/epidemiology, education.field_of_study, SARS-CoV-2/isolation & purification, Middle Aged, Viral/epidemiology, Geography, Research Design, Original Article, Switzerland, 360 Social problems & social services, Adolescent, Adult, Aged, Antibodies, Viral/blood, Betacoronavirus/immunology, Ethnic Groups, Humans, Pandemics, Pneumonia, Viral/epidemiology, Young Adult, Hygiene practices, Longitudinal, SARS-CoV-2, medicine.medical_specialty, Population, Pneumonia, Viral, Antibodies, Health(social science), 03 medical and health sciences, Betacoronavirus, Environmental health, medicine, Seroprevalence, education, ddc:613, Public health, Public Health, Environmental and Occupational Health, COVID-19, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), 2739 Public Health, Environmental and Occupational Health, Pneumonia, ddc:618.97
Abstract

Objectives: Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general population and subgroups are key for evaluating mitigation and vaccination policies and for understanding the spread of the disease both on the national level and for comparison with the international community. Methods: Corona Immunitas is a research program of coordinated, population-based, seroprevalence studies implemented by Swiss School of Public Health (SSPH+). Over 28,340 participants, randomly selected and age-stratified, with some regional specificities will be included. Additional studies in vulnerable and highly exposed subpopulations are also planned. The studies will assess population immunological status during the pandemic. Results: Phase one (first wave of pandemic) estimates from Geneva showed a steady increase in seroprevalence up to 10.8% (95% CI 8.2-13.9, n = 775) by May 9, 2020. Since June, Zurich, Lausanne, Basel City/Land, Ticino, and Fribourg recruited a total of 5973 participants for phase two thus far. Conclusions: Corona Immunitas will generate reliable, comparable, and high-quality serological and epidemiological data with extensive coverage of Switzerland and of several subpopulations, informing health policies and decision making in both economic and societal sectors. ISRCTN Registry: https://www.isrctn.com/ISRCTN18181860 ., + ID der Publikation: unilu_50428 + Sprache: Englisch + Letzte Aktualisierung: 2020-11-02 15:42:18

Published
2020
Full Text
View/download PDF

39. The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research

Author

Nina Steinemann, Jens Kuhle, Pasquale Calabrese, Jürg Kesselring, Giulio Disanto, Doron Merkler, Caroline Pot, Vladeta Ajdacic-Gross, Stephanie Rodgers, Milo Alan Puhan, Viktor von Wyl, the Swiss Multiple Sclerosis Registry, Swiss Multiple Sclerosis Registry, Anderseck, B., Calabrese, P., Chan, A., Disanto, G., Engelhardt, B., Gobbi, C., Häussler, R., Kamm, C.P., Kägi, S., Kesselring, J., Kuhle, J., Kurmann, R., Lotter, C., Luyckx, K., Merkler, D., Monin, P., Müller, S., Nedeltchev, K., Pot, C., Puhan, M.A., Rapold, I., Salmen, A., Schippling, S., Vaney, C., von Wyl, V., University of Zurich, and von Wyl, Viktor

Subjects
Research design, Adult, medicine.medical_specialty, Biomedical Research, Adolescent, Epidemiology, Health-related quality of life, Population, 610 Medicine & health, ddc:616.07, lcsh:RC346-429, Multiple sclerosis, 03 medical and health sciences, Study Protocol, Young Adult, 0302 clinical medicine, Clinical Protocols, Patient-Centered Care, Surveys and Questionnaires, Health care, medicine, Humans, 030212 general & internal medicine, Prospective Studies, Registries, Patient participation, education, lcsh:Neurology. Diseases of the nervous system, education.field_of_study, Data collection, Patient-reported outcomes, business.industry, Medical record, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), General Medicine, Biomedical Research/methods, Multiple Sclerosis/epidemiology, Multiple Sclerosis/therapy, Patient Participation, Research Design, Switzerland/epidemiology, Switzerland, 2728 Neurology (clinical), Family medicine, 570 Life sciences, biology, Neurology (clinical), Design and Technology, business, 030217 neurology & neurosurgery
Abstract

Multiple sclerosis (MS) is one of the most frequently observed neurological conditions in Switzerland, but data sources for country-wide epidemiological trend monitoring are lacking. Moreover, while clinical and laboratory MS research are generally well established, there is a gap in patient-centered MS research to inform care management, or treatment decisions and policy making not only in Switzerland but worldwide. In light of these research gaps, the Swiss Multiple Sclerosis Society initiated and funded the Swiss Multiple Sclerosis Registry (SMSR) an open-ended, longitudinal and prospective, nationwide, patient-centered study. The SMSR recruits adult persons with a suspected or confirmed MS diagnosis who reside or receive care in Switzerland. The SMSR has established a governance structure with clear rules and guidelines. It follows a citizen-science approach with direct involvement of persons with MS (PwMS), who contribute actively to registry development, operations, and research. Main scientific goals entail the study of MS epidemiology in Switzerland, health care access and provision, as well as life circumstances and wellbeing of persons with MS. The innovative study design (“layer model”) offers several participation options with different time commitments. Data collection is by means of regular surveys and medical record abstraction. Survey participation is offered in different modes (web, paper & pencil) and in the three main national languages (German, French, Italian). Participants also receive regular data feedbacks for personal use and self-monitoring, contextualized in the whole population of study participants. Data feedbacks are also used to solicit data corrections of key variables from participants. The SMSR combines the advantages of traditional and novel research methods in medical research and has recruited over 1600 PwMS in its first year. The future-oriented design and technology will enable a response not only to future technological innovations and research trends, but also to challenges in health care provision for MS. ClinicalTrials.gov NCT02980640 ; December 6, 2016; retrospectively registered.

Published
2018

40. Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIV-1 Reverse Transcriptase

Author

Viktor, von Wyl, Maryam, Ehteshami, Jori, Symons, Philippe, Bürgisser, Monique, Nijhuis, Lisa M, Demeter, Sabine, Yerly, Jürg, Böni, Thomas, Klimkait, Rob, Schuurman, Bruno, Ledergerber, Matthias, Götte, Huldrych F, Günthard, S, Yerly, Swiss HIV Cohort Study, University of Zurich, and von Wyl, V

Subjects
viruses, Context (language use), 610 Medicine & health, HIV Infections, Drug resistance, Statistics, Nonparametric, Cell Line, 10234 Clinic for Infectious Diseases, 03 medical and health sciences, Zidovudine, Drug Resistance, Multiple, Viral, immune system diseases, medicine, Immunology and Allergy, Humans, heterocyclic compounds, Selection, Genetic, 030304 developmental biology, Genetics, 0303 health sciences, biology, 030306 microbiology, Lamivudine, virus diseases, 2725 Infectious Diseases, biochemical phenomena, metabolism, and nutrition, HIV Infections/drug therapy, HIV Infections/virology, HIV Reverse Transcriptase/genetics, HIV Reverse Transcriptase/metabolism, HIV-1/genetics, Lamivudine/pharmacology, Reverse Transcriptase Inhibitors/pharmacology, Zidovudine/pharmacology, biology.organism_classification, Resistance mutation, Virology, Reverse transcriptase, HIV Reverse Transcriptase, 3. Good health, Infectious Diseases, Ribonuclease H, Human Immunodeficiency Virus, Mutation (genetic algorithm), Lentivirus, DNA, Viral, Mutation, 2723 Immunology and Allergy, HIV-1, Reverse Transcriptase Inhibitors, Drug Therapy, Combination, medicine.drug
Abstract

BACKGROUND: The connection domain mutation N348I confers resistance to zidovudine (AZT) and is associated with the lamivudine (3TC) mutation M184V. We explored the biochemical and virological influence of N348I in the context of M184V. METHODS: Genotypic resistance data for patients receiving monotherapy or dual therapy with AZT, lamivudine (3TC), or AZT/3TC were analyzed. Rates of N348I emergence were compared between treatment groups. Mutant reverse transcriptases (RTs) containing M184V and/or N348I were generated to study enzymatic and virological properties. RESULTS: We included 50 AZT-treated, 11 3TC-treated, and 10 AZT/3TC-treated patients. N348I was observed in 3 (6%), 0, and 4 (40%) of these patients, respectively. The rate of N348I emergence was increased by 5-fold in the AZT/3TC group (11.7 instances [95% confidence interval {CI}, 3.2-30.1 instances] per 100 person-years of receipt of AZT), compared with the rate noted for the AZT group (2.3 instances [95% CI, 0.4-6.8 instances] per 100 person-years of receipt of AZT; P = .04). Biochemical data show that N348I can partially compensate for the diminution in processive DNA synthesis and the reduction in AZT excision associated with M184V. Furthermore, virological analyses demonstrate that N348I confers low-level resistance to AZT and partly restores the reduced RT activity of the M184V variant. CONCLUSION: In vivo selection of N348I is driven by AZT and is further facilitated when 3TC is coadministered. Compensatory interactions between N348I and M184V help to explain these findings.

Published
2010
Full Text
View/download PDF

41. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic

Author

Wandeler, Gilles, Gsponer, Thomas, Bregenzer, Andrea, Günthard, Huldrych F, Clerc, Olivier, Calmy, Alexandra, Stöckle, Marcel, Bernasconi, Enos, Furrer, Hansjakob, Rauch, Andri, Swiss HIV Cohort Study, University of Zurich, Wandeler, Gilles, Swiss HIV Cohort Study, Barth, J., Battegay, M., Bernasconi, E., Böni, J., Bucher, HC., Bürgisser, P., Burton-Jeangros, C., Calmy, A., Cavassini, M., Dubs, R., Egger, M., Elzi, L., Fehr, J., Fischer, M., Flepp, M., Francioli, P., Furrer, H., Fux, CA., Gorgievski, M., Günthard, H., Hasse, B., Hirsch, HH., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Müller, N., Nadal, D., Pantaleo, G., Rauch, A., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schöni-Affolter, F., Schüpbach, J., Speck, R., Taffé, P., Telenti, A., Trkola, A., Vernazza, P., and von Wyl, V.

Subjects
Male, HIV Infections, Hepatitis C/epidemiology/virology, medicine.disease_cause, 2726 Microbiology (medical), Men who have sex with men, Serology, 10234 Clinic for Infectious Diseases, Cohort Studies, 0302 clinical medicine, Switzerland/epidemiology, Risk Factors, 030212 general & internal medicine, Substance Abuse, Intravenous, 610 Medicine & health, ddc:616, Incidence (epidemiology), Incidence, virus diseases, Hepatitis C, HIV Infections/epidemiology/virology, 3. Good health, Infectious Diseases, 030211 gastroenterology & hepatology, Female, Switzerland, Cohort study, Microbiology (medical), Adult, Hepatitis C virus, Substance Abuse, Intravenous/epidemiology/virology, Statistics, Nonparametric, 03 medical and health sciences, medicine, Humans, Homosexuality, Male, Seroconversion, Epidemics, Chi-Square Distribution, business.industry, 2725 Infectious Diseases, medicine.disease, Virology, digestive system diseases, Homosexuality, Male/statistics & numerical data, Immunology, Syphilis, business
Abstract

BACKGROUND: Hepatitis C virus (HCV) infection has a growing impact on morbidity and mortality in patients infected with human immunodeficiency virus (HIV). We assessed trends in HCV incidence in the different HIV transmission groups in the Swiss HIV Cohort Study (SHCS). METHODS: HCV infection incidence was assessed from 1998, when routine serial HCV screening was introduced in the SHCS, until 2011. All HCV-seronegative patients with at least 1 follow-up serology were included. Incidence rates (IRs) of HCV infections were compared between men who have sex with men (MSM), injection drug users (IDU), and heterosexuals (HET). RESULTS: HCV incidence was assessed in 3333 MSM, 123 IDU, and 3078 HET with a negative HCV serology at baseline. Over 23 707 person-years (py) for MSM, 733 py for IDU, and 20 752 py for HET, 101 (3%), 41 (33%), and 25 (1%) of patients seroconverted, respectively. The IR of HCV infections in MSM increased from 0.23 (95% credible interval [CrI], .08-.54) per 100 py in 1998 to 4.09 (95% CrI, 2.57-6.18) in 2011. The IR decreased in IDU and remained

Published
2012

42. Resurgence of HIV infection among men who have sex with men in Switzerland: mathematical modelling study

Author

André Jeannin, A.I. van Sighem, Tracy R. Glass, Heiner C. Bucher, F. De Wolf, Daniela Bezemer, Christophe Fraser, Pietro Vernazza, Martin D. Gebhardt, S Derendinger, Beatriz Vidondo, Nicola Low, Swiss HIV Cohort Study, Barth, J., Battegay, M., Bernasconi, E., Böni, J., Bucher, HC., Bürgisser, P., Burton-Jeangros, C., Calmy, A., Cavassini, M., Egger, M., Elzi, L., Fehr, J., Fischer, M., Flepp, M., Francioli, P., Furrer, H., Fux, CA., Gorgievski, M., Günthard, H., Hasse, B., Hirsch, HH., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Müller, N., Nadal, D., Pantaleo, G., Rauch, A., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schöni-Affolter, F., Schüpbach, J., Speck, R., Taffé, P., Telenti, A., Trkola, A., Vernazza, P., von Wyl, V., Weber, R., and Yerly, S.

Subjects
Adult, Male, Cart, Sexual Behavior, HIV Infections/epidemiology, HIV Infections/transmission, Homosexuality, Male, Humans, Incidence, Models, Statistical, Prevalence, Public Health Surveillance, Switzerland/epidemiology, HIV prevention, Sexually Transmitted Diseases, Human immunodeficiency virus (HIV), lcsh:Medicine, Population Modeling, HIV Infections, Viral diseases, medicine.disease_cause, Men who have sex with men, Public health surveillance, Acquired immunodeficiency syndrome (AIDS), Medicine, lcsh:Science, Hiv transmission, Biology, Multidisciplinary, Risk behaviour, business.industry, Incidence (epidemiology), lcsh:R, Computational Biology, HIV, virus diseases, medicine.disease, AIDS, HIV epidemiology, Immunology, Infectious diseases, lcsh:Q, Public Health, Preventive Medicine, Infectious Disease Modeling, Behavioral and Social Aspects of Health, business, Switzerland, Research Article, Demography
Abstract

Background New HIV infections in men who have sex with men (MSM) have increased in Switzerland since 2000 despite combination antiretroviral therapy (cART). The objectives of this mathematical modelling study were: to describe the dynamics of the HIV epidemic in MSM in Switzerland using national data; to explore the effects of hypothetical prevention scenarios; and to conduct a multivariate sensitivity analysis. Methodology/Principal Findings The model describes HIV transmission, progression and the effects of cART using differential equations. The model was fitted to Swiss HIV and AIDS surveillance data and twelve unknown parameters were estimated. Predicted numbers of diagnosed HIV infections and AIDS cases fitted the observed data well. By the end of 2010, an estimated 13.5% (95% CI 12.5, 14.6%) of all HIV-infected MSM were undiagnosed and accounted for 81.8% (95% CI 81.1, 82.4%) of new HIV infections. The transmission rate was at its lowest from 1995–1999, with a nadir of 46 incident HIV infections in 1999, but increased from 2000. The estimated number of new infections continued to increase to more than 250 in 2010, although the reproduction number was still below the epidemic threshold. Prevention scenarios included temporary reductions in risk behaviour, annual test and treat, and reduction in risk behaviour to levels observed earlier in the epidemic. These led to predicted reductions in new infections from 2 to 26% by 2020. Parameters related to disease progression and relative infectiousness at different HIV stages had the greatest influence on estimates of the net transmission rate. Conclusions/Significance The model outputs suggest that the increase in HIV transmission amongst MSM in Switzerland is the result of continuing risky sexual behaviour, particularly by those unaware of their infection status. Long term reductions in the incidence of HIV infection in MSM in Switzerland will require increased and sustained uptake of effective interventions.

Published
2012

43. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption

Author

Sara Gianella, Bernard Hirschel, Andri Rauch, Matthias Cavassini, Enos Bernasconi, Manuel Battegay, Barbara Niederoest, Viktor von Wyl, Beda Joos, Huldrych F. Günthard, Herbert Kuster, Swiss Hiv Cohort Study-SHCS, Marek Fischer, Pietro Vernazza, Rainer Weber, Swiss HIV Cohort Study-SHCS, Weaver, Eric A, University of Zurich, and von Wyl, V

Subjects
Male, Cross-sectional study, Adult *Antiretroviral Therapy, lcsh:Medicine, HIV Infections, 030312 virology, Global Health, 10234 Clinic for Infectious Diseases, Cohort Studies, 0302 clinical medicine, immune system diseases, Antiretroviral Therapy, Highly Active, HIV Seropositivity, 030212 general & internal medicine, Viral, Longitudinal Studies, lcsh:Science, 0303 health sciences, Multidisciplinary, virus diseases, HIV diagnosis and management, Viral Load, Antivirals, 3. Good health, Infectious Diseases, HIV epidemiology, 6.1 Pharmaceuticals, Medicine, Infectious diseases, HIV/AIDS, RNA, Viral, HIV clinical manifestations, Biological Markers, Female, Infection, Viral load, Cohort study, Research Article, Cart, Viral/blood Female Follow-Up Studies HIV Infections/*drug therapy/*virology HIV Seropositivity HIV-1/*genetics Humans Longitudinal Studies Male RNA, Adult, medicine.medical_specialty, Drugs and Devices, Infectious Disease Control, Clinical Research Design, General Science & Technology, Antiretroviral Therapy, Viral/blood *Viral Load, 610 Medicine & health, 1100 General Agricultural and Biological Sciences, Viral diseases, Microbiology, Adult *Antiretroviral Therapy, Highly Active Biomarkers/*blood CD4 Lymphocyte Count Case-Control Studies Cohort Studies Cross-Sectional Studies DNA, Viral/blood Female Follow-Up Studies HIV Infections/*drug therapy/*virology HIV Seropositivity HIV-1/*genetics Humans Longitudinal Studies Male RNA, Viral/blood *Viral Load, 03 medical and health sciences, 1300 General Biochemistry, Genetics and Molecular Biology, Clinical Research, Internal medicine, Virology, mental disorders, MD Multidisciplinary, medicine, Highly Active Biomarkers/*blood CD4 Lymphocyte Count Case-Control Studies Cohort Studies Cross-Sectional Studies DNA, Humans, Highly Active, Seroconversion, Biology, 1000 Multidisciplinary, business.industry, lcsh:R, Case-control study, HIV, Evaluation of treatments and therapeutic interventions, DNA, Antiretroviral therapy, Confidence interval, Swiss HIV Cohort Study-SHCS, CD4 Lymphocyte Count, Cross-Sectional Studies, nervous system, Case-Control Studies, Immunology, DNA, Viral, HIV-1, RNA, lcsh:Q, business, Biomarkers, Follow-Up Studies
Abstract

Background: Long-term benefits of combination antiretroviral therapy (cART) initiation during primary HIV-1 infection are debated. Methods: The evolution of plasma HIV-RNA (432 measurements) and cell-associated HIV-DNA (325 measurements) after cessation of cART (median exposure 18 months) was described for 33 participants from the Zurich Primary HIV Infection Study using linear regression and compared with 545 measurements from 79 untreated controls with clinically diagnosed primary HIV infection, respectively a known date for seroconversion. Results: On average, early treated individuals were followed for 37 months (median) after cART cessation; controls had 34 months of pre-cART follow-up. HIV-RNA levels one year after cART interruption were 20.8 log10 copies/mL [95% confidence interval 21.2;20.4] lower in early treated patients compared with controls, but this difference was no longer statistically significant by year three of follow-up (20.3 [20.9; 0.3]). Mean HIV-DNA levels rebounded from 2 log10 copies [1.8; 2.3] on cART to a stable plateau of 2.7 log10 copies [2.5; 3.0] attained 1 year after therapy stop, which was not significantly different from cross-sectional measurements of 9 untreated members of the control group (2.8 log10 copies [2.5; 3.1]). Conclusions: The rebound dynamics of viral markers after therapy cessation suggest that early cART may indeed limit reservoir size of latently infected cells, but that much of the initial benefits are only transient. Owing to the non-randomized study design the observed treatment effects must be interpreted with caution.

Published
2011

44. Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study

Author

Séverine Louvel, Gladys Martinetti, Enos Bernasconi, Pietro Vernazza, Huldrych F. Günthard, Heiner C. Bucher, Hans H. Hirsch, Jan Fehr, Thomas Klimkait, Sabine Yerly, Christoph A Fux, Viktor von Wyl, Manuel Battegay, Bernard Hirschel, François Hamy, Philippe Bürgisser, Tracey R. Glass, Matthias Cavassini, Jürg Böni, University of Zurich, Klimkait, T, Swiss HIV Cohort Study, Battegay, M., Bernasconi, E., Böni, J., Bucher, HC., Bürgisser, P., Calmy, A., Cattacin, S., Cavassini, M., Dubs, R., Egger, M., Elzi, L., Fehr, J., Fischer, M., Flepp, M., Francioli, P., Furrer, H., Fux, CA., Gorgievski, M., Günthard, HF., Hasse, B., Hirsch, HH., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Müller, N., Nadal, D., Paccaud, F., Pantaleo, G., Rauch, A., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schöni-Affolter, F., Schüpbach, J., Speck, R., de Tejada BM., Taffé, P., Telenti, A., Trkola, A., Vernazza, P., von Wyl, V., Weber, R., and Yerly, S.

Subjects
Oncology, 10028 Institute of Medical Virology, Male, Multivariate analysis, viruses, lcsh:Medicine, HIV Infections, Virus Replication, 10234 Clinic for Infectious Diseases, Cohort Studies, 0302 clinical medicine, Genotype, 030212 general & internal medicine, Virus Replication/drug effects/physiology, Medicine(all), ddc:616, 0303 health sciences, Adult, Anti-HIV Agents/pharmacology, Anti-HIV Agents/therapeutic use, Dose-Response Relationship, Drug, Drug Resistance, Viral/physiology, Female, HIV Infections/diagnosis, HIV Infections/drug therapy, HIV-1/physiology, Humans, Microbial Sensitivity Tests/methods, Middle Aged, Phenotype, Predictive Value of Tests, Prognosis, Switzerland, Virus Replication/drug effects, Virus Replication/physiology, General Medicine, HIV Infections/diagnosis/drug therapy/virology, 3. Good health, Predictive value of tests, Cohort study, medicine.medical_specialty, Anti-HIV Agents, 610 Medicine & health, Microbial Sensitivity Tests, General Biochemistry, Genetics and Molecular Biology, Virus, 03 medical and health sciences, 1300 General Biochemistry, Genetics and Molecular Biology, Internal medicine, Drug Resistance, Viral, medicine, Anti-HIV Agents/pharmacology/therapeutic use, 030304 developmental biology, Biochemistry, Genetics and Molecular Biology(all), business.industry, Research, lcsh:R, Odds ratio, Institutional repository, Viral replication, Immunology, HIV-1, 570 Life sciences, biology, business
Abstract

Background Replicative phenotypic HIV resistance testing (rPRT) uses recombinant infectious virus to measure viral replication in the presence of antiretroviral drugs. Due to its high sensitivity of detection of viral minorities and its dissecting power for complex viral resistance patterns and mixed virus populations rPRT might help to improve HIV resistance diagnostics, particularly for patients with multiple drug failures. The aim was to investigate whether the addition of rPRT to genotypic resistance testing (GRT) compared to GRT alone is beneficial for obtaining a virological response in heavily pre-treated HIV-infected patients. Methods Patients with resistance tests between 2002 and 2006 were followed within the Swiss HIV Cohort Study (SHCS). We assessed patients' virological success after their antiretroviral therapy was switched following resistance testing. Multilevel logistic regression models with SHCS centre as a random effect were used to investigate the association between the type of resistance test and virological response (HIV-1 RNA Results Of 1158 individuals with resistance tests 221 with GRT+rPRT and 937 with GRT were eligible for analysis. Overall virological response rates were 85.1% for GRT+rPRT and 81.4% for GRT. In the subgroup of patients with >2 previous failures, the odds ratio (OR) for virological response of GRT+rPRT compared to GRT was 1.45 (95% CI 1.00-2.09). Multivariate analyses indicate a significant improvement with GRT+rPRT compared to GRT alone (OR 1.68, 95% CI 1.31-2.15). Conclusions In heavily pre-treated patients rPRT-based resistance information adds benefit, contributing to a higher rate of treatment success.

Published
2010

45. HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy

Author

Viktor, von Wyl, Maryam, Ehteshami, Lisa M, Demeter, Philippe, Bürgisser, Monique, Nijhuis, Jori, Symons, Sabine, Yerly, Jürg, Böni, Thomas, Klimkait, Rob, Schuurman, Bruno, Ledergerber, Matthias, Götte, Huldrych F, Günthard, S, Yerly, University of Zurich, von Wyl, V, Swiss HIV Cohort Study, Battegay, M., Bernasconi, E., Böni, J., Bucher, HC., Bürgisser, P., Calmy, A., Cattacin, S., Cavassini, M., Dubs, R., Egger, M., Elzi, L., Fischer, M., Flepp, M., Fontana, A., Francioli, P., Furrer, H., Fux, CA., Gorgievski, M., Günthard, HF., Hirsch, HH., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Karrer, U., Kind, C., Klimkait, T., Ledergerber, B., Martinetti, G., Müller, N., Nadal, D., Paccaud, F., Pantaleo, G., Rauch, A., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schüpbach, J., Speck, R., de Tejada BM., Taffé, P., Telenti, A., Trkola, A., Vernazza, P., Weber, R., and Yerly, S.

Subjects
Microbiology (medical), medicine.medical_specialty, Combination therapy, Genotype, Anti-HIV Agents, 610 Medicine & health, Drug resistance, 2726 Microbiology (medical), 10234 Clinic for Infectious Diseases, 03 medical and health sciences, Zidovudine, 0302 clinical medicine, Molecular genetics, Drug Resistance, Viral, medicine, Humans, 030212 general & internal medicine, 030304 developmental biology, Retrospective Studies, 0303 health sciences, biology, Nucleoside analogue, Base Sequence, business.industry, Lamivudine, 2725 Infectious Diseases, biology.organism_classification, Virology, Reverse transcriptase, HIV Reverse Transcriptase, 3. Good health, Infectious Diseases, Lentivirus, Mutation, HIV-1, Drug Therapy, Combination, business, medicine.drug, Anti-HIV Agents/administration & dosage, Anti-HIV Agents/therapeutic use, HIV Reverse Transcriptase/genetics, HIV Reverse Transcriptase/metabolism, HIV-1/drug effects, HIV-1/enzymology
Abstract

BACKGROUND: Factors promoting the emergence of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) connection domain mutations and their effect on antiretroviral therapy (ART) are still largely undetermined. We investigated this matter by analyzing genotypic resistance tests covering 400 amino acid positions in the RT of HIV-1 subtype B viruses and corresponding treatment histories and laboratory measurements. METHODS: The emergence of connection domain mutations was studied in 334 patients receiving monotherapy or dual therapy with thymidine analogues at the time of the genotypic resistance test. Response to subsequent combination ART (cART) was analyzed using Cox regression for 291 patients receiving unboosted protease inhibitors. Response was defined by ever reaching an HIV RNA level

Published
2010

46. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland

Author

Jürg Böni, Sebastian Bonhoeffer, Sabine Yerly, Pietro Vernazza, Philippe Bürgisser, Hansjakob Furrer, Thomas Klimkait, Huldrych F. Günthard, Bruno Ledergerber, Enos Bernasconi, Matthias Cavassini, Viktor von Wyl, Manuel Battegay, P Francioli, Bernard Hirschel, University of Zurich, and von Wyl, V

Subjects
Microbiology (medical), 10028 Institute of Medical Virology, Adult, Male, medicine.medical_specialty, Genotype, Anti-HIV Agents, Context (language use), HIV Infections, 610 Medicine & health, Drug resistance, 2726 Microbiology (medical), 10234 Clinic for Infectious Diseases, Young Adult, Switzerland/epidemiology, Acquired immunodeficiency syndrome (AIDS), Internal medicine, Epidemiology, Drug Resistance, Viral, medicine, Prevalence, Humans, HIV Infections/ drug therapy/epidemiology/ virology, Sida, ddc:616, HIV-1/ drug effects/genetics, biology, business.industry, 2725 Infectious Diseases, Middle Aged, biology.organism_classification, medicine.disease, Multiple drug resistance, Infectious Diseases, Anti-HIV Agents/therapeutic use, Cohort, Immunology, HIV-1, 570 Life sciences, Female, Viral disease, business, Switzerland
Abstract

Clinical Infectious Diseases, 48 (7), ISSN:1058-4838, ISSN:1537-6591

Published
2009

47. High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease

Author

Jörg, Schüpbach, Leslie R, Bisset, Stephan, Regenass, Philippe, Bürgisser, Meri, Gorgievski, Ingrid, Steffen, Corinne, Andreutti, Gladys, Martinetti, Cyril, Shah, Sabine, Yerly, Thomas, Klimkait, Martin, Gebhardt, Franziska, Schöni-Affolter, Martin, Rickenbach, J, Barth, M, Battegay, E, Bernascon, J, Böni, H C, Bucher, P, Bürgisser, C, Burton-Jeangros, A, Calmy, M, Cavassini, R, Dubs, M, Egger, L, Elzi, J, Fehr, M, Fischer, M, Flepp, P, Francioli, H, Furrer, C A, Fux, M, Gorgievski, H, Günthard, B, Hasse, H H, Hirsch, B, Hirschel, I, Hösli, C, Kahlert, L, Kaiser, O, Keiser, C, Kind, T, Klimkait, H, Kovari, B, Ledergerber, G, Martinetti, B, Martinez de Tejada, N, Müller, D, Nadal, G, Pantaleo, A, Rauch, S, Regenass, M, Rickenbach, C, Rudin, P, Schmid, D, Schultze, F, Schöni-Affolter, J, Schüpbach, R, Speck, P, Taffé, A, Telenti, A, Trkola, P, Vernazza, V, von Wyl, R, Weber, S, Yerly, Barth, J., Battegay, M., Bernascon, E., Böni, J., Bucher, H.C., Bürgisser, P., Burton-Jeangros, C., Calmy, A., Cavassini, M., Dubs, R., Egger, M., Elzi, L., Fehr, J., Fischer, M., Flepp, M., Francioli, P., Furrer, H., Fux, C.A., Gorgievski, M., Günthard, H., Hasse, B., Hirsch, H.H., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Müller, N., Nadal, D., Pantaleo, G., Rauch, A., Regenass, S., Rudin, C., Schmid, P., Schultze, D., Schöni-Affolter, F., Schüpbach, J., Speck, R., Taffé, P., Telenti, A., Trkola, A., Vernazza, P., von Wyl, V., Weber, R., Yerly, S., University of Zurich, and Schüpbach, J

Subjects
Adult, Male, 10028 Institute of Medical Virology, medicine.medical_specialty, HIV Infections, 610 Medicine & health, Disease, Logistic regression, Sensitivity and Specificity, lcsh:Infectious and parasitic diseases, Algorithms, Clinical Laboratory Techniques/methods, Female, HIV Infections/diagnosis, HIV-1/classification, HIV-1/genetics, Humans, Immunoassay, RNA, Viral/blood, Virology/methods, Serology, 10234 Clinic for Infectious Diseases, Medical microbiology, Antigen, Virology, medicine, lcsh:RC109-216, ddc:616, biology, Clinical Laboratory Techniques, virus diseases, 2725 Infectious Diseases, Infectious Diseases, Parasitology, Immunology, HIV-1, 10033 Clinic for Immunology, biology.protein, RNA, Viral, 570 Life sciences, Antibody, Algorithm, Research Article, Cohort study
Abstract

Background: Serologic testing algorithms for recent HIV seroconversion (STARHS) provide important information for HIV surveillance. We have shown that a patient’s antibody reaction in a confirmatory line immunoassay (INNOLIA TM HIV I/II Score, Innogenetics) provides information on the duration of infection. Here, we sought to further investigate the diagnostic specificity of various Inno-Lia algorithms and to identify factors affecting it. Methods: Plasma samples of 714 selected patients of the Swiss HIV Cohort Study infected for longer than 12 months and representing all viral clades and stages of chronic HIV-1 infection were tested blindly by Inno-Lia and classified as either incident (up to 12 m) or older infection by 24 different algorithms. Of the total, 524 patients received HAART, 308 had HIV-1 RNA below 50 copies/mL, and 620 were infected by a HIV-1 non-B clade. Using logistic regression analysis we evaluated factors that might affect the specificity of these algorithms. Results: HIV-1 RNA

Full Text
View/download PDF

48. What Gets Measured Gets Managed: A Scoping Review of Musculoskeletal Research Conducted Within Practice-Based Research Networks.

Author

Lalji R, Muñoz Laguna J, Kauth J, Hofstetter L, Kurmann A, Adams J, Kongsted A, von Wyl V, Puhan MA, and Hincapié CA

Subjects
Humans, Biomedical Research, Primary Health Care organization & administration, Health Services Research, Musculoskeletal Diseases therapy
Abstract

Abstract: Musculoskeletal conditions are often managed in primary care settings. To facilitate research and healthcare quality, practice-based research networks offer sustained collaborations between clinicians and researchers. A scoping review was conducted to describe characteristics of practice-based research networks used for musculoskeletal research and musculoskeletal research conducted through practice-based research networks. Practice-based research networks were identified from 1) musculoskeletal-studies identified in OVID Medline, CINAHL, and Embase databases from inception to 5 February 2023 and in ClinicalTrials.gov and 2) from practice-based research network registries and websites. Among active musculoskeletal-focused practice-based research networks (i.e., currently recruiting and conducting research), an assessment of practice-based research network research good practices was performed. After screening 3025 records, 85 studies from 46 unique practice-based research networks met our eligibility criteria. Common conditions studied were low back pain (28%), musculoskeletal conditions not otherwise specified (25%), and osteoarthritis (19%). Thirty-two practice-based research networks (70%) were deemed to be active. Among active musculoskeletal-focused practice-based research networks, best practice data management information was retrievable for most (53%). Because of the scarcity of publicly available information, a large proportion of practice-based research network research good practice items was not assessable. Practice-based research networks have provided an avenue to assess clinical practice and patient outcomes related to musculoskeletal conditions. Further work to increase the transparency of musculoskeletal practice-based research network research practices is warranted., Competing Interests: Author disclosures: This work was internally supported with a grant to the University of Zurich from the Foundation for the Education of Chiropractors in Switzerland. The funders had no role in study conceptualization and design, or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the manuscript for publication. The authors declare no conflicts of interest and no financial incentives were provided. This work has not been previously presented in any form prior to this submission. Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)

Published
2024
Full Text
View/download PDF

49. Socioeconomic Status and Adherence to Preventive Measures During the COVID-19 Pandemic in Switzerland: A Population Based Digital Cohort Analysis.

Author

Tancredi S, van der Linden BWA, Chiolero A, Cullati S, Imboden M, Probst-Hensch N, Keidel D, Witzig M, Dratva J, Michel G, Harju E, Frank I, Lorthe E, Baysson H, Stringhini S, Kahlert CR, Bardoczi JB, Haller ML, Chocano-Bedoya PO, Rodondi N, Amati R, Albanese E, Corna L, Crivelli L, Kaufmann M, Frei A, and von Wyl V

Subjects
Humans, Switzerland epidemiology, Male, Female, Middle Aged, Adult, Aged, Cohort Studies, Patient Compliance statistics & numerical data, Pandemics, COVID-19 prevention & control, COVID-19 epidemiology, Social Class, SARS-CoV-2
Abstract

Objectives: To assess the association between socioeconomic status (SES) and self-reported adherence to preventive measures in Switzerland during the COVID-19 pandemic., Methods: 4,299 participants from a digital cohort were followed between September 2020 and November 2021. Baseline equivalised disposable income and education were used as SES proxies. Adherence was assessed over time. We investigated the association between SES and adherence using multivariable mixed logistic regression, stratifying by age (below/above 65 years) and two periods (before/after June 2021, to account for changes in vaccine coverage and epidemiological situation)., Results: Adherence was high across all SES strata before June 2021. After, participants with higher equivalised disposable income were less likely to adhere to preventive measures compared to participants in the first (low) quartile [second (Adj.OR, 95% CI) (0.56, 0.37-0.85), third (0.38, 0.23-0.64), fourth (0.60, 0.36-0.98)]. We observed similar results for education., Conclusion: No differences by SES were found during the period with high SARS-CoV-2 incidence rates and stringent measures. Following the broad availability of vaccines, lower incidence, and eased measures, differences by SES started to emerge. Our study highlights the need for contextual interpretation when assessing SES impact on adherence to preventive measures., Competing Interests: The authors declare that they do not have any conflicts of interest., (Copyright © 2024 Tancredi, van der Linden, Chiolero, Cullati, Imboden, Probst-Hensch, Keidel, Witzig, Dratva, Michel, Harju, Frank, Lorthe, Baysson, Stringhini, Kahlert, Bardoczi, Haller, Chocano-Bedoya, Rodondi, Amati, Albanese, Corna, Crivelli, Kaufmann, Frei and von Wyl.)

Published
2024
Full Text
View/download PDF

50. Citizen Views on an Opt-Out Approach to National Electronic Health Records in Germany: A Small-Scale Qualitative Study.

Author

Papadopoulos K, Struckmann V, von Wyl V, and Gille F

Subjects
Humans, Germany, Female, Male, Middle Aged, Adult, Aged, Electronic Health Records, Focus Groups, Qualitative Research, Public Opinion
Abstract

Objectives: Electronic health records (German: elektronische Patientenakte - ePA) are an important healthcare tool. However, in Germany, current participation remains low for their national ePA. To rectify this, the German government recently adopted an opt-out approach to their national ePA system. The objective of this study is to investigate and provide a brief overview of German public attitudes towards this approach to inform policymakers with evidence-based insights., Methods: Four public focus groups were conducted with 12 German citizens to discuss their opinions on the German governments new opt-out approach to the ePA., Results: Three major thematic categories were identified (Contributors to Opt-Out Implementation, Barriers to Opt-Out Implementation, and Contingent Factors) to describe citizen views on the opt-out approach for the ePA., Conclusion: The public is generally supportive of an opt-out approach to ePAs in Germany, as they see the benefits ePAs can provide to German society; but they are skeptical on how successful this approach might be due to extant issues that policymakers must be aware of in order to successfully implement an opt-out approach for Germany's national ePA system., Competing Interests: FG receives funding from Novartis AG, Stiftung Sanitas Krankenversicherung, Schweizerische Akademie der Technischen Wissenschaften outside of the submitted work. The remaining authors declare that they do not have any conflicts of interest., (Copyright © 2024 Papadopoulos, Struckmann, von Wyl and Gille.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results